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Glioblastoma Multiforme (GBM) is a highly aggressive and devastating primary brain 
tumour with a prognosis of 12-15 months with standard of care treatments, which 
includes combinations of surgery, radiotherapy and chemotherapy. Aggressiveness, 
among other factors, is driven by the populations of brain tumour initiating cells, capable 
of self renewal, tumour recapitulation and high therapy resistance. Dinaciclib is a potent 
cyclin-dependent kinase (CDK) inhibitor (CKI) which inhibits GBM cell growth in vitro. 
This study confirmed the growth inhibition of GBM cells but also demonstrated 
enrichment for specific brain tumour initiating cell populations upon dinaciclib treatment. 
In the zebrafish (Danio rerio) model, dinaciclib showed less toxicity to the developing 
embryos than NU2058, another CKI with similar CDK targets. Embryos injected with 
U87 cells, a GBM cell line, were treated with dinaciclib and we demonstrated that there 
was a decrease in cell foci area after treatment with dinaciclib compared to the vehicle 
control. The breast cancer cells, MDA-MB-231, were also injected into zebrafish 
embryos to perform a comparative analysis of spatial trends in cell metastasis. 
Interestingly, there appears to be a preferential migration of injected cancer cells to the 
organ of cancer origin, with GBM cells migrating towards the brain and head and breast 
cancer cells migrating down the tail. In summary, we demonstrated that using a CKI 
simultaneously with a chemotherapy induces antagonistic effects in GBM cells, which 









I would like to start my acknowledgements with Dr. Lisa Porter, who has been extremely 
patient and kind, and was willing to give me the opportunity to obtain this Master’s 
degree, thank you. 
I would like to thank my committee members, Dr. Huiming Zhang and Dr. John Trant, 
for their time, advice, and review of this work. 
A critical acknowledgement goes out to Dr. Dorota Lubanska, for her guidance and 
support. You are incredibly kind and generous, and this degree would not be possible 
without you, thank you. 
I would like to acknowledge Janice Tubman and Martin Bakht. Janice for her help all 
things zebrafish, injections and image analysis included. Martin for his general guidance 
and advice throughout this degree. I would not have accomplished this feat without the 
two of you, thank you. 
I would like to thank Dr. Bre-Anne Fifield and Dr. Elizabeth Fidalgo da Silva for their 
direct help with me at times and for the everyday work they do to maintain the lab.  
I would like to acknowledge Dr. Keith Frank Stringer, to which I have been a bad “wing-
man” and I would like to officially apologize for that. Frank is a hard worker, punctual, 
and puts in more hours in the lab than anyone else I know (aside from maybe Martin). 
Buy Bitcoin. 
Thank you to the rest of the Porter Lab group, everyone has tolerated my shenanigans 





TABLE OF CONTENTS 
 
DECLARATION OF CO-AUTHORSHIP ........................................................................ iii 
ABSTRACT ....................................................................................................................... iv 
ACKNOWLEDGEMENTS .................................................................................................v 
LIST OF TABLES ........................................................................................................... viii 
LIST OF FIGURES ........................................................................................................... ix 
LIST OF ABBREVIATIONS/SYMBOLS ..........................................................................x 
INTRODUCTION ...............................................................................................................1 
1. Glioblastoma Multiforme..........................................................................................1 
2. Main Obstacles in GBM Treatment. .........................................................................1 
2.1. Cancer Stem Cells/Brain Tumour Initiating Cells .................................................1 
2.2. The Blood-Brain Barrier ........................................................................................4 
3. The Cell Cycle and Cancer .......................................................................................6 
4. Common CNS Chemotherapies and Synthetic CKIs................................................9 
4.1. Standard of Care and Other Chemotherapy ...........................................................9 
4.2. Synthetic CKIs .....................................................................................................11 
4.3. Drug Interactions and Bliss Independence Model ...............................................12 
5. Zebrafish as a High-Throughput in vivo Model ......................................................13 
6. Hypothesis and Objectives ......................................................................................18 
MATERIALS AND METHODS .......................................................................................19 
1. Cell Culture .............................................................................................................19 
2. MTT Assay and Bliss Independence Model ...........................................................19 
3. Immunocytochemistry ............................................................................................21 
4. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)..........................22 
5. Animal Care and Toxicity Screen ...........................................................................23 
6. Zebrafish Injections ................................................................................................23 
7. Zebrafish Imaging and Analysis .............................................................................24 




9. Statistical Analysis ..................................................................................................25 
RESULTS ..........................................................................................................................27 
1. Selected CKIs and Chemotherapeutics Have an Antagonistic Relationship ..........27 
2. Dinaciclib Selects for a Stem-like Population of GBM Cells .................................33 
3. Total Foci are Reduced in vivo with Dinaciclib Treatment ....................................37 
4. Dinaciclib Reduces Metastases Proximal to the Brain ...........................................42 
DISCUSSION ....................................................................................................................45 
REFERENCES/BIBLIOGRAPHY....................................................................................53 






LIST OF TABLES 






























LIST OF FIGURES 
Figure 1: Anatomy and immune development of the zebrafish embryo. ......................... 15 
Figure 2: EC50 values and inhibition curves of GBM cell lines. ...................................... 29 
Figure 3: U87 matrix plots of synergy distribution from combination of a CKI and 
chemotherapy. ................................................................................................................... 30 
Figure 4: U251 surface plots and the corresponding matrix plots of synergy distribution 
from combination of a CKI and chemotherapy. ............................................................... 32 
Figure 5: Dinaciclib decreases cell numbers and induces apoptosis in combination with 
TMZ. ................................................................................................................................. 36 
Figure 6: Schematic of zebrafish injections. ..................................................................... 38 
Figure 7: Dinaciclib reduces relative tumour area. ........................................................... 41 













LIST OF ABBREVIATIONS/SYMBOLS 
 
ABC……………………………………..……..……………………ATP-binding cassette 




BTIC…………………………..……………………………….brain tumour initiating cell 
CC-3…………………………………..…………………………...…….cleaved caspase-3 
CD…………………………………………....…………………...cluster of differentiation 
CDK...…….………………………………………..……………..cyclin-dependent kinase 
CEC……...………………………………………………cerebrovascular endothelial cells 
Chk1……………..…………………………………………...………..checkpoint kinase 1 
Chk2……………………..…………….………………………………checkpoint kinase 2 
CKI……………………………..…………...…………..cyclin-dependent kinase inhibitor 
CNS.…………………………………..……………………………central nervous system 
CSC………………………………………………………………………..cancer stem cell 
CSF………………………………………………..…………..………..cerebrospinal fluid 
dpf……….……………………………..………………..…………..days post-fertilization 





EC50……………………..………….………………..half maximal effective concentration 
EMEM……………………….…………….…………Eagle’s minimum essential medium 
ESA………………………………..…………………..………...epithelial specific antigen  
FBS………………………………………..………………………….…fetal bovine serum 
FDA…………………………..…………………...The US Food and Drug Administration  
FOV……………………………………………………..…………………….field of view 
HBSS……..…………………………………………………Hanks Balanced Salt Solution 






IC50 ……...…………………..…………………...……….inhibitory concentration of 50% 
Ki………………………..………………………………………..…the inhibitory constant 
M………………………………..……………………………………………….….mitosis 
MAP2………………………………………………...…..microtubule associated protein 2 
MTIC………………………...………...3-methyl-(triazen-1-yl) imidazole-4-carboxamide 
MTT………………………………………….……...Thiazolyl Blue Tetrazolium Bromide 
PBS….……………………………………………..…..……...phosphate buffered solution  





qRT-PCR………..……………....…….Quantitative Real-Time polymerase chain reaction  
RINGO………………………………...… Rapid Inducer of G2/M Progression in Oocytes 




WHO……...………………………………………….………..World Health Organization 





1. Glioblastoma Multiforme 
The most common primary brain tumours are gliomas, which originate from glial cells in 
the brain (Seliger & Hau, 2018). The World Health Organization (WHO) has classified 
gliomas from low (I-II) to high (III-IV) grade, based on aggressiveness and patient 
prognosis, with the most aggressive cancer, Glioblastoma Multiforme (GBM), classified 
as a grade IV glioma (Louis et al., 2016). GBM is very heterogeneous and demonstrates 
high genomic instability, making the recurrent tumour more aggressive and resistant to 
treatment. The average lifespan of GBM patients after diagnosis, under the standard of 
care, is 12-15 months (Zimmer et al., 2019). GBM patients undergo a very aggressive 
treatment regimen, beginning with maximal surgical resection, followed by radiotherapy 
and chemotherapy (Jia, Wang, Yin, & Liu, 2019). Chemotherapy almost always consists 
of temozolomide (TMZ), which may or may not be beneficial for patients, depending on 
the methylation status of MGMT, a gene known to inhibit the function of TMZ. This 
indicates a significant problem in current treatment options for GBM patients, as patients 
are still being treated with TMZ achieving complete response at a rate of only 11% 
(Gilbert et al., 2002). 
2. Main Obstacles in GBM Treatment. 
2.1. Cancer Stem Cells/Brain Tumour Initiating Cells 
Cancer stem cells (CSCs) play an essential role in therapy resistance and tumour relapse 
in cancer (Brown et al., 2017). It is now known that CSCs represent a small 
subpopulation of cells within tumours and have stemness characteristics such as capacity 




(Kreso & Dick, 2014). The first evidence of CSCs was in acute myeloid leukemia 
(AML), with the AML-initiating cells being identified based on the expression of a cell 
surface marker, the cluster of differentiation 34 (CD34+), and the absence of the marker, 
cluster of differentiation 38 (CD38-) (Lapidot et al., 1994). Different types of CSCs can 
be isolated in the lab based on their cell surface marker expression status, which includes 
CD44+/CD24- (breast cancer) (Al-Hajj, Wicha, Benito-Hernandez, Morrison, & Clarke, 
2003), CD133+/CD24+/ESA+ (pancreas) (Li et al., 2007) and CD133+, CD44+ (glioma) 
(Hemmati et al., 2003; Singh et al., 2004).  
Glioma CSCs are also referred to as brain tumour initiating cells (BTICs) and 
glioma stem cells (GSCs), and will be referred to as BTICs in this thesis. There is data to 
support that BTICs cause therapy resistance and tumour recurrence (Brown et al., 2017; 
Singh et al., 2004). They are often characterized by expression of proteins such as 
CD133, CD44, SOX2, and OCT4, to name a few (Bradshaw et al., 2016; Brown et al., 
2017; Singh et al., 2004). CD44, a transmembrane glycoprotein involved in migration 
and invasion, and angiogenesis, is used by BTICs and contributes to aggressiveness of 
tumours (Senbanjo & Chellaiah, 2017). Spy1, also known as Speedy or RINGO, is a non-
cyclin cell cycle regulator protein which is also found to be highly expressed in GBM 
(Ferby, Blazquez, Palmer, Eritja, & Nebreda, 1999; Lenormand, Dellinger, Knudsen, 
Subramani, & Donoghue, 1999; Lubanska et al., 2014). Spy1 binds to and activates 
cyclin-dependent kinase 2 (CDK2) independent of cyclin binding, allowing for a 
premature G1/S phase transition in the cell cycle. Spy1 also promotes cell survival in 
response to DNA damage caused by genotoxic agents (Barnes, Porter, Lenormand, 




increasing stages of glioma, with grade III glioma and GBM having the highest levels. 
Lubanska et al. showed that Spy1 advances the expansion of CD133+ BTIC populations, 
possibly through the Numb/Notch pathway, making Spy1 a valid marker for BTIC 
expansion (Lubanska et al., 2014). 
Current chemotherapies largely target cancer cells based on their high 
proliferation, affecting the rapidly dividing cells of the tumour. However, BTICs, like 
CSCs found in other tissues, have a slower rate of division and thus mediate 
chemoresistance and tumour recurrence following treatment (Baumann, Krause, & Hill, 
2008; Eyler & Rich, 2008). There are other mechanisms contributing to the 
chemoresistance of BTICs, which include the expression of ATP-binding cassette (ABC) 
transporters. The ABC transporter proteins are a superfamily of membrane proteins 
capable of converting energy from ATP hydrolysis to transport various substrates across 
the cell membrane (Begicevic & Falasca, 2017). The ABC transporters C1 and B1 are 
both highly expressed in BTICs and act to actively efflux many drugs, including TMZ, 
etoposide, doxorubicin, and paclitaxel, among many others (Kolenda et al., 2011; Xi et 
al., 2016). Hence ABC transporters contribute to the chemoresistance in BTICs that make 
treating GBM particularly challenging. Another factor contributing to the drug resistance 
in BTICs is the ability of these cells to activate the DNA damage response and repair 
machinery (Maugeri-Sacca, Bartucci, & De Maria, 2012). BTICs can activate the ataxia-
telangiectasia-mutated (ATM) serine/threonine kinase as well as the DNA damage 
checkpoint kinases 1 (Chk1) and 2 (Chk2) in response to ionizing radiation, allowing the 
BTICs to stall the cell cycle and repair DNA to avoid apoptosis (Bao et al., 2006). In 




patients, and it is important to find drugs or treatment methods that target this population 
of cells to improve the prognosis in GBM patients. 
2.2. The Blood-Brain Barrier 
A major issue in treating most central nervous system (CNS) diseases, including brain 
cancers, is the ability to readily cross the blood-brain barrier (BBB). The BBB is a 
semipermeable membrane that separates the brain from the circulating blood supply. 
Consisting of different cell types such as cerebrovascular endothelial cells (CECs), 
pericytes, astrocytes, and microglial cells, the BBB is a complex network of cells 
providing an essential function to all vertebrates (Bundgaard & Abbott, 2008; Wang et 
al., 2018). The CECs form tight junctions between cells and are usually the prominent 
barrier in preventing molecules from crossing into the brain fluid (Wang et al., 2018). 
The BBB allows for the passage of some molecules by passive diffusion, and other 
critical molecules for proper neural function via selective transport, such as water, amino 
acids, and glucose (Groothuis, 2000; Liebner, Czupalla, & Wolburg, 2011). The BBB is 
an essential protective barrier to the most sensitive organ in the body; it is responsible for 
limiting pathogens, solutes in blood, and large or hydrophilic molecules from entering the 
cerebrospinal fluid (CSF). Although it does allow the diffusion of small hydrophobic 
molecules such as O2 and CO2, as well as small polar molecules, such as acetaminophen, 
the BBB is a major obstacle in the treatment of most CNS diseases, including brain 
cancer, by limiting the access of therapeutic drugs to cross into the CSF (Johansen et al., 
2018; Stamatovic, Keep, & Andjelkovic, 2008). This also poses an obstacle in testing of 
new drug targets at the clinical level and impairing any progress in therapy. There are two 




Da, and the drug must form less than 8-10 hydrogen bonds with water (Cardoso, Brites, 
& Brito, 2010; Pardridge, 2005). These criteria can be used as a general rule when 
developing new drugs for treatment of diseases within the CNS, but a clinical trial will 
verify the actual amount of drug that effectively crosses the BBB. Unfortunately, current 
approach to drug development is focused on the target effect, and less effort is spent on 
the delivery of the drug (Pardridge, 2009). One method to get around the BBB in the 
treatment of GBM is through the use of a Gliadel® wafer. Carmustine, also known as 
BCNU, is infused in the Gliadel® wafer, which is implanted under the skull in the space 
left after the surgery to remove the GBM tumour. The wafer slowly dissolves, releasing 
the drug into the space left after surgery (Xing, Shao, Qi, Yang, & Wang, 2015). 
Although carmustine can readily cross the BBB, it has fewer toxic effects when used in a 
wafer. This method allows for other large molecules to be applied directly to the former 
tumour site. The Gliadel® wafer improves survival rates, but the drug delivery over time 
is short and not ideal, as the majority of drug is released in the first week (Domb et al., 
1995; Shapira-Furman et al., 2019). The ideal wafer would release a consistent amount of 
drug over a longer time period. This method illustrates one way to treat GBM without 
having to consider the BBB. Another method of getting around the BBB is through the 
use of pulsed ultrasound with injected microbubbles – microscopic bubbles of an 
innocuous gas surrounded in a lipid coating – direct into the bloodstream. These 
microbubbles will vibrate and disrupt the BBB when ultrasound is applied, and this 
vibration disrupts the BBB and allows for drug passage that would not occur with an 
intact BBB (Carpentier et al., 2016). Disruption of the BBB is a new and experimental 




3. The Cell Cycle and Cancer 
The cell cycle consists of four separate phases, with checkpoints in-between and within 
phases. The first growth phase, called Gap 1 phase (G1), is where cells gather enough 
nutrients to duplicate their DNA. The second phase is S phase, or synthesis phase, where 
DNA is synthesized. The third phase is the Gap 2 phase (G2), where more nutrients are 
taken up and the cell prepares for the last phase, mitosis or M phase, where the cell 
undergoes mitosis and divides into two daughter cells. Cells have the capacity to enter a 
non-growth phase, G0, before it commits to replicating DNA. Most non-dividing, non-
growing cells in the human body, such as neurons and myocytes, are resting in the G0 
phase (Norbury & Nurse, 1992). There are also four well characterized checkpoints in the 
cell cycle, the first being located at the end of the G1 phase, which checks for DNA 
damage, growth factors, and cell size. The next checkpoint is in the S phase, where there 
is continual control of DNA quality as DNA is being replicated. There is a checkpoint at 
the transition of the G2 to M phase, which is similar to the checkpoint at the end of the G1 
phase, checking for DNA damage, sufficient nutrients and proper cell size to complete M 
phase. The last checkpoint is during M phase at the beginning of anaphase, called the 
spindle assembly checkpoint, which checks that chromosomes are aligned, and 
centromeres are properly attached to the microtubules for equal distribution. The 
checkpoints in the cell cycle are critical in maintaining healthy cells, by stopping the cell 
cycle after damage, the cell can repair the damage or follow apoptosis and eliminate any 
potentially harmful mutations (Kastan & Bartek, 2004).  
The two major protein classes regulating the cell cycle are cyclins and CDKs. 




writing, but the major cyclins involved in cell cycle regulation include cyclins A, B, D, 
and E. Not all cyclins or CDKs are involved in cell cycle regulation, but the major CDKs 
which are involved include CDKs 1, 2, 4, and 6 (Li, Qian, & Sun, 2019; Shen, Dean, Yu, 
& Duan, 2019; Vermeulen, Van Bockstaele, & Berneman, 2003).  
CDKs consist of a family of serine/threonine protein kinases, which are 
constitutively expressed in cells, whereas specific cyclins are synthesized at specific 
points in the cell cycle, hence their namesake. CDKs form a complex with cyclins, and 
most CDKs have both activating and inhibitory phosphorylation sites that cause 
conformational changes which may allow the complex to form and become activated 
(Lim & Kaldis, 2013; Vermeulen, Van Bockstaele, & Berneman, 2003). These 
complexes push the cell through the checkpoints in-between the phases in the cell cycle. 
To be more specific, it is the binding of CDK4 and CDK6 to the group of cyclin D 
(cyclin D1, cyclin D2, and cyclin D3), and the downstream phosphorylation events from 
this complex, which are responsible for entry into the early G1 phase (Sherr, 1994). 
Cyclin E-CDK2 complex is responsible for promoting the transition from G1 to S phase 
(Ohtsubo, Theodoras, Schumacher, Roberts, & Pagano, 1995); CDK2 also binds with 
cyclin A and this complex is required for transition through S phase (Girard, Strausfeld, 
Fernandez, & Lamb, 1991; Walker & Maller, 1991). Cyclin A-CDK1 complex promotes 
the cell into the M phase, and the cyclin B1-CDK1 complex is also responsible for 
regulation in mitosis (Arellano & Moreno, 1997).  
CDK activity is also regulated by another protein family, called CDK inhibitors 
(CKIs), which consist of two major groups; the INK4 family, which bind to CDK 4/6 




complex (Carnero & Hannon, 1998; Hengst & Reed, 1998). The INK4 proteins consist of 
p15INK4b, p16INK4a, p18INK4c, and p19INK4d, which inhibit CDKs 4 and 6 by forming stable 
complexes with CDK enzyme before binding with cyclin D, and thus block progression 
of the cell cycle past the G1 checkpoint (Kim & Sharpless, 2006; Ortega, Malumbres, & 
Barbacid, 2002). INK4 proteins are tumour suppressor proteins that play a role in 
apoptosis, DNA repair, and senescence (Canepa et al., 2007; Roussel, 1999). The three 
proteins of the CIP/KIP family include p21cip1/waf1, p27kip1, and p57kip2 (Harper et al., 
1995; Lee, Reynisdottir, & Massague, 1995; Polyak et al., 1994), and their main action is 
inhibiting the G1/S and S phase CDKs (CDK1 and CDK2) (Sherr & Roberts, 1999). 
Unlike the INK4 family, the CIP/KIP proteins have CDK independent roles in the cell, 
which include the regulation of transcription, apoptosis, and the cytoskeleton (Besson, 
Gurian-West, Schmidt, Hall, & Roberts, 2004; Coqueret, 2003; Wang, Elson, & Leder, 
1997). The CIP/KIP family of proteins are responsible for inhibiting the cell cycle in the 
G1 phase, inhibiting mostly the CDK2/4-cyclin complexes (Roskoski, 2019). 
The cell cycle has many connections to the hallmarks of cancer (Hanahan & 
Weinberg, 2011). Mutations causing the inactivation of CKIs such as in p16, p21, and 
p27, remove the checkpoints in the cell cycle, allowing the cell to progress and divide. 
This allows for uncontrolled cell growth and evasion of apoptosis, as well as genomic 
instability, which contributes to tumour evolution (Hanahan & Weinberg, 2011; Williams 
& Stoeber, 2012). The CDKs involved directly in regulating the cell cycle are 
upregulated and often have increased activity in many cancers (Otto & Sicinski, 2017). 
Inhibition of CDK2 in BTICs causes a downregulation of Sox2 levels, which is involved 




amplifications of CDK 4 and 6, as well as deletions or inactivating mutations of 
CDKN2A, which codes for p16 and p14, responsible for inhibiting CDK4 and CDK6 
(Bronner et al., 2019). Other members of the CDK family are also involved in cancer, 
which include CDK5, which promotes invasion and migration by down regulating the 
actin regulatory protein caldesmon (Cheung & Ip, 2012; Quintavalle, Elia, Price, 
Heynen-Genel, & Courtneidge, 2011), CDK8 has been identified as a coactivator of the 
β-catenin pathway in colon cancer (Firestein et al., 2008), and CDK10 causes resistance 
to endocrine therapy in breast cancer (Iorns et al., 2008).  
4. Common CNS Chemotherapies and Synthetic CKIs  
4.1. Standard of Care and Other Chemotherapy  
Currently the two most commonly used chemotherapy drugs for GBM treatment are 
TMZ and carmustine (Minniti, Muni, Lanzetta, Marchetti, & Enrici, 2009; Rahman et al., 
2014). TMZ acts by alkylating/methylating DNA, at the N-7 or O-6 position of guanine 
(Zhang, Stevens, & Bradshaw, 2012). This DNA damage signals the cell for apoptosis, 
making it a useful chemotherapy. The action of TMZ can be counteracted by the DNA 
repair gene MGMT, an enzyme capable of repairing the mutagenic lesion of O6-
methylguanine. The methylation status of the promoter of MGMT is a very powerful 
prognostic marker in GBM. The methylated MGMT promoter results in the repression of 
the MGMT protein, and therefore repression in DNA repair allowing for successful 
action of TMZ (Wang et al., 2019). In 2004, a study by Hegi et al. showed that patients 
with methylated MGMT promoter and treated with radiotherapy and TMZ had a median 
survival of 21.7 months, compared to 15.3 months in patients treated with only 




increased amount of the MGMT repair protein, the comparable survival rates were 12.7 
and 11.8 months, respectively (Hegi et al., 2005). Unfortunately, the standard of care in 
GBM treatment includes TMZ, regardless of MGMT methylation status. 
TMZ or its derivatives can be delivered to a patient either intravenously or orally 
and can be administered in combination with various treatment regimens. The current 
standard treatment regimen is daily oral administration of 150-200 mg/m2 for 5 days over 
a 28-day treatment cycle for 6 cycles following radiotherapy (Gilbert et al., 2013). TMZ 
requires first-pass metabolism to be activated, making it a prodrug, which is a compound 
that is pharmacologically activated after it has been administered and metabolized. At 
physiological pH, TMZ is metabolized into 3-methyl-(triazen-1-yl) imidazole-4-
carboxamide (MTIC), which splits into two other metabolites responsible for methylating 
DNA (Agarwala & Kirkwood, 2000). The second most used drug in GBM treatment is 
carmustine, which is used in Gliadel® wafers inserted directly into the brain at the time 
of surgery. Carmustine is an alkylating agent that can cause the formation of interstrand 
crosslinks in DNA (Weiss & Issell, 1982; Woolley, Dion, Kohn, & Bono, 1976). Another 
drug which is used to treat GBM, among other cancers, is Etoposide, a topoisomerase II 
inhibitor (Tonder, Weller, Eisele, & Roth, 2014). It forms a stable complex with DNA 
and topoisomerase II, which prevents re-ligation and leads to double strand breaks in the 
DNA (Chen, Chan, & Hsieh, 2013; Wilstermann et al., 2007; Wu et al., 2011). This leads 
to a stop largely at the G2/M checkpoint in the cell cycle (Higginbottom, Cummings, 
Newland, & Allen, 2002; Nam, Doi, & Nakayama, 2010). These drugs represent the 
conventional chemotherapy approach, non-specifically targeting rapidly growing cells 




4.2. Synthetic CKIs 
Natural CKIs are frequently mutated or deleted in cancer, allowing for unregulated cell 
proliferation (Bailon-Moscoso, Cevallos-Solorzano, Romero-Benavides, & Orellana, 
2017; Johansson & Persson, 2008; Sharma, Sharma, & Tyagi, 2008). Since the 
downregulation of natural CKIs contributes to cancer progression, generation of synthetic 
CKIs has the potential to aid in eradication of therapy resistant cancer cells. The first 
synthetic CKI identified was flavopiridol in 1992, a pan-CDK inhibitor that inhibits 
CDKs 1, 2, 4, 6 and 7 (Kaur et al., 1992; Sedlacek, 2001). Since then there have been 
many synthetic CKIs developed and tested against cancer and a host of other diseases. 
The first FDA approved CKI, palbociclib, an inhibitor of CDKs 4 and 6, was approved 
for use in metastatic estrogen receptor positive breast cancer in combination with 
letrozole in 2015 (Morikawa & Henry, 2015), and there are now two other FDA approved 
CKIs as of this writing, abemaciclib and ribociclib (Kim, 2017; Mullard, 2017).  
There are currently many clinical trials involving CKIs as single agent use or in 
combination with other chemotherapies. One such CKI is dinaciclib, a potent second 
generation CKI which targets CDKs 1, 2, 5, and 9 (Parry et al., 2010). Dinaciclib is 
currently in phase I and II clinical trials with one completed phase III trial. One study 
found dinaciclib, in combination with Bcl-2/Bcl-xL inhibitors, significantly reduced 
GBM cell proliferation independent of p53 status (Jane et al., 2016). Dinaciclib binds to 
the ATP site of CDK2 with an intricate network of hydrogen bonds and van der Waals 
forces, which explains its high potency and selectivity for CDK2 (Martin, Olesen, Georg, 
& Schonbrunn, 2013). Dinaciclib thus has great potential for treatment of GBM, as 




Lubanska & Porter, 2017; Molenaar et al., 2009). As a relatively new and understudied 
drug, there is little known about dinaciclib, including any first pass effects or whether it 
would be a good candidate drug used to cross the BBB. Clinical trials involving 
dinaciclib have included cancers such as leukemia, melanoma, non-small-cell lung 
cancer, and prostate cancer, but there are no trials involving GBM or any other brain 
cancers (Nemunaitis et al., 2013; Rello-Varona et al., 2019). Due to its potency in vitro 
and promising number of clinical trials for other types of cancer, it is of high importance 
to test the effectiveness of this compound against BTICs.  
O6-cyclohexylmethylguanine, referred to hereafter as NU2058, is an inhibitor of 
CDK2 and CDK1, with Ki values of 12 ± 3 and 5 ± 1 µM, respectively. The Ki is defined 
as the inhibitory constant and is reflective of the binding affinity of compounds. NU2058 
binds to the ATP binding pocket of CDK2, in a distinct position which differs from other 
purine-based inhibitors, such as roscovotine (Arris et al., 2000; Hardcastle et al., 2004; 
Rigas, Robson, & Curtin, 2007). The pharmacology of CKIs such as first-pass 
metabolism and half-life are lacking, and the field requires further research. 
4.3. Drug Interactions and Bliss Independence Model 
Drug interactions are an important aspect of every anti-cancer regimen due to their ability 
to either diminish or enhance the action of an individual drug in the applied combination. 
Drug interactions can be additive in effect, which is the expected result when the drugs 
have no interactions; synergistic, the effect of interacting drugs is larger than the expected 
additive result; and antagonistic, the reduced outcome from the expected additive results 
(Greco, Bravo, & Parsons, 1995). The use of a drug as a monotherapy has its limits and 




inadequate and the heterogenous tumour typically relapses from the resistant CSCs 
(Spiro, Kovacs, & Csermely, 2008). Synergy between drugs is very important in treating 
cancer. When two or more drugs are used, synergistic effects are desirable because of 
increased efficacy and the decreased dosage used with the same or greater than expected 
efficacy as opposed to the drugs used alone. The decreased dosage of synergistic drugs 
causes fewer toxic effects seen in patients, and in general, drugs used in combination 
delay the progress of drug resistance (Jia et al., 2009). 
There are a few common methods used to calculate the drug interactions, which 
include the Bliss independence model, Loewe additivity, and the Chou-Talalay method 
(Bliss, 1939; Chou & Talalay, 1977; Loewe, 1928). These models are important in 
determining which drugs can be used synergistically against cancer. These methods used 
to calculate drug interactions address the same question but from different viewpoints. 
Conceptually, the Bliss independence model emphasizes the treatment effect 
enhancement, while the Loewe additivity model emphasizes on dose reduction, making 
the Bliss independence model a more suitable model to study chemotherapy drug 
combinations (Lotsch & Geisslinger, 2011; Zhao et al., 2014). The Bliss independence 
model assumes no interaction between drugs and the combined drugs have different 
mechanisms of action or target sites from each other (Foucquier & Guedj, 2015; 
Pemovska, Bigenzahn, & Superti-Furga, 2018).  
5. Zebrafish as a High-Throughput in vivo Model 
Animal models play an essential role in the development of novel anti-cancer drugs. Mice 
have been established as the golden standard for model organisms when investigating 




between humans and mice, amongst many other reasons (Lampreht Tratar, Horvat, & 
Cemazar, 2018). Despite multiple advantages of employing mice, mouse models are 
relatively expensive and labour intensive, diminishing their utility in high-throughput 
drug screening studies. Zebrafish (Danio rerio) have been established as an animal model 
for developmental genetics in the 1960’s (Streisinger, Walker, Dower, Knauber, & 
Singer, 1981). Approximately 70% of protein coding genes in zebrafish have their human 
orthologs (Howe et al., 2013), and zebrafish do have similar physiology to humans, 
which include organs such as heart, liver, and pancreas. These organs perform much of 
the same functions as their human counterparts, such as the BBB, which is functionally 
conserved in zebrafish and contain proteins responsible for tight junctions in the human 
BBB, such as claudin-5 and ZO-1 (Fleming, Diekmann, & Goldsmith, 2013; O’Brown, 
Pfau, & Gu, 2018). Another example is the cardiac electrophysiology, which in zebrafish 
is more similar to humans than humans are to mice, with a comparable electrocardiogram 
(ECG) between humans and zebrafish (Asnani & Peterson, 2014; Chi et al., 2008; 
MacRae & Peterson, 2015). Additionally, cytochrome P450 is a family of enzymes 
responsible for oxidation of endogenous and exogenous chemicals. In humans, these 
enzymes are responsible for about 75% of drug metabolism. Zebrafish have a total of 94 
cytochrome P450 genes, most of which are direct orthologs of human cytochrome P450 
(Goldstone et al., 2010). A representative image of a zebrafish embryo aged 4 days post 





Figure 1: Anatomy and immune development of the zebrafish embryo.  
(A) Image of a zebrafish embryo aged 4dpf with labelled anatomy. (B) Simplified 
timeline of the immune system development in zebrafish. Note the adaptive immune 
system (T- and B-cells) are not active until 2-4 weeks post fertilization. Image of 






Furthermore, zebrafish have become an efficient tumour xenotransplantation 
model first described by Lee et al. in 2005, who transplanted melanoma cells into the 
blastodisc of very young (3.5 hours post fertilization) zebrafish embryos, promoting the 
idea of zebrafish for tumour-based experiments (Lee, Seftor, Bonde, Cornell, & Hendrix, 
2005). There are many advantages for the use of zebrafish as an animal model in tumour 
xenotransplantation studies in comparison to mice. One advantage is the rapid embryonic 
development, giving researchers eggs in less than 24 hours to work with. Compared to 
mice with a gestation period of 21 days, zebrafish allow for faster experiments. Zebrafish 
prefer to be housed in large groups, called shoals, and are much smaller requiring far less 
maintenance than mice (Streisinger, Walker, Dower, Knauber, & Singer, 1981). 
Zebrafish also produce many more spawn than mice, producing around 100-200 eggs per 
breeding pair, compared to an average of 7-12 pups per litter in mice (Lampreht Tratar, 
Horvat, & Cemazar, 2018; Mullins, Hammerschmidt, Haffter, & Nusslein-Volhard, 1994; 
Streisinger, Walker, Dower, Knauber, & Singer, 1981). The development of the immune 
system in zebrafish (Figure 1B) plays a critical role for the use of zebrafish in cancer 
research. The adaptive immune system of the zebrafish is not fully active until fish are 
around 21 days old, and there is an immature innate immune response starting at 24 hours 
post fertilization (hpf). This allows for a primitive immune response against bacterium, 
but injected cells are not detected by this innate immune system, allowing for tumour 
transplantation at an early developmental stage without the need for genetically altered 
immunocompromised organisms (Lam, Chua, Gong, Lam, & Sin, 2004; Lieschke & 
Trede, 2009; Meijer & Spaink, 2011; Traver et al., 2003). Cells undergoing 




express fluorescent protein in the cytoplasm, and then injected into the zebrafish, 
commonly into the yolk sac of the developing embryo but can also be injected 
orthotopically (the transplantation of specific tissue into its normal place in the body) and 
as a xenograft in immunocompromised adult fish (Wertman, Veinotte, Dellaire, & 
Berman, 2016). Because the embryos are transparent (Figure 1A), real-time live imaging 
in zebrafish is relatively easy, and transparent adult zebrafish lines have been developed 
allowing for live imaging at the single cell level, something not easily achieved in mice 
(Ghotra et al., 2012; Spitsbergen, 2007; Stoletov, Montel, Lester, Gonias, & Klemke, 
2007; White et al., 2008; Zhao, Tang, Cui, Ang, & Wong, 2009).  
Recent work has suggested that zebrafish can be a great model for the 
development of patient-personalized care, as patient-derived cells can be successfully 
xenografted into adult immunocompromised fish and treated with different drug 
combinations by orally gavaging fish (Yan et al., 2019). Zebrafish have been established 
as a model organism for drug screening because they produce many progenies per 
breeding pair, and there is enough fish that can be used to statistically evaluate the 
outcomes. This is typically done in multi-well plates and embryos can be placed in 
groups per well or individually in a single well. By performing drug screens this way, 
many drugs, as well as many drug combinations, can be tested at the same time (Gibert, 
Trengove, & Ward, 2013; MacRae & Peterson, 2015). All the advantages listed above 
contribute to the cost effectiveness of zebrafish, adding yet another advantage of 




6. Hypothesis and Objectives 
Hypothesis: Synthetic CKIs in combination with chemotherapy play an important role in 
treatment of glioma cells and demonstrate characteristics advantageous for potential 
combination therapy for patients with GBM.  
Objectives: The first objective is to assess the effectiveness of a CKI and chemotherapy 
as a combination therapy on GBM in vitro. The second objective is to characterize the 
GBM cell populations post-treatment. Finally, the last objective is to assess the 




















MATERIALS AND METHODS 
1. Cell Culture 
U-87 MG wild-type (WT) cells were obtained from ATCC and maintained in growth 
media containing Eagle’s minimum essential medium (EMEM) (Quality Biological, 
#112-018-101) supplemented with 10% fetal bovine serum (FBS) (Gibco, #10437028) 
and 1% penicillin and streptomycin (Invitrogen, #15140148). Once cells reached 70-80% 
confluency, plates were washed with serum-free EMEM and 700µL of 0.25% trypsin 
(Hyclone, #SH3023601) was added and plate was incubated at 37°C for 3-5 minutes. 
Cells were cultured at 37°C in 5% CO2 environment. 
U-251 MG WT cells were a kind gift from Dr. Rutka (SickKids Hospital, 
Toronto) maintained in EMEM growth media supplemented with 10% FBS, 1mM 
sodium pyruvate, 1% non-essential amino acids, and 1% penicillin and streptomycin. 
Once cells reached 80-90% confluency, plates were washed with serum-free EMEM and 
700 µL of 0.25% trypsin was added and plate was incubated at 37°C for 5 minutes. Cells 
were cultured at 37°C in 5% CO2 environment. 
 MDA-MB-231 (HTB26; ATCC) cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Sigma) supplemented with 10% FBS and 1% penicillin and 
streptomycin and were maintained in an atmosphere of 5% CO2 at 37˚C.  
2. MTT Assay and Bliss Independence Model 
Cell viability was determined using an MTT (Thiazolyl Blue Tetrazolium Bromide) 
assay. Cells were seeded in a 96-well plate at a density of 5x103 cells/well in a total of 
100µL growth media, 24 hours before drug treatment began. The growth media was then 




drugs TMZ (Selleckchem, #S1237), etoposide (Santa Cruz, #sc-3512), NU2058 (Santa 
Cruz, #sc-202744A), and dinaciclib (Selleckchem, #S2768) every 24 hours for 3 
consecutive days. After 24 hours of the last drug treatment, growth media was removed 
and 100µL of a 50% mix of MTT solution (5mg/mL Thiazolyl Blue Tetrazolium 
Bromide in filter sterilized PBS) (Sigma Aldrich, #M5655) and serum-free EMEM media 
was added to the wells. The plate was then immediately incubated at 37°C for 3 hours, 
then 150 µL of MTT solvent (4 mM HCl, 0.1% NP40 in isopropanol) was added to each 
well and left on an orbital shaker for 15 minutes. Within one hour, plate was read on a 
SpectraMax plate reader (Molecular Devices) for absorbance at OD=590 nm. The EC50 
values were calculated using the free software Combenefit (Di Veroli et al., 2016). EC50 
is defined as the half maximal effective concentration, and the quantal dose response 
curve was calculated, which is the concentration of a compound where 50% of the 
population exhibit a response. 
 The Bliss independence model was used for analysis of all combination drug 
treatments. The Combenefit software (Di Veroli et al., 2016) was used to determine the 
drug interactions using the Bliss model. The Bliss equation is as follows: 
Yab,P = Ya + Yb - YaYb 
Where Yab,P is the predicted percent inhibition, Ya is percent of inhibition from drug A at 
dose a, and Yb is the percent of inhibition from drug B at dose b. Then the observed 
percentage inhibition is calculated in the same way, denoted as Yab,O, which is then 
compared to the Yab,P value. If Yab,O = Yab,P then there is an additive effect, if Yab,O > 




Yab,P then there is an antagonistic relationship of the two drugs in question (Zhao et al., 
2014). 
3. Immunocytochemistry 
Cells were grown on coverslips in 6-well plates at 37°C and 5% CO2. Growth medium 
was aspirated off adherent cells and washed with warmed PBS twice. Cells were then 
fixed with 1 mL of 4% paraformaldehyde (PFA) for 15 minutes, then 800 µL were 
removed and 800 µL of PBS was added to each well. Plates were then wrapped in 
parafilm and stored at -20°C until ready for continuation. Once ready, PFA/PBS mixture 
was removed, cells were washed again with PBS, and coverslips were moved onto 
labelled parafilm. Cells were washed 3 times with PBS-Triton Wash Buffer (0.05% 
Triton X-100 in PBS) for 5 minutes each time. Cells were then blocked with blocking 
buffer for 1 hour at room temperature. The primary antibodies CD44 (Novus, #NBP1-
31488) (3.3:400), Ki67 (Abcam, #ab15580) (1:400), and CC-3 (cleaved caspase-3) (Cell 
signalling, #9661S) (1:400) were prepared in 50% blocking buffer solution and 50% 
PBS-Triton wash buffer, and 100 µL drops were placed on parafilm per coverslip. 
Coverslips were placed cell side down onto primary antibody mixture and moved to a 
humidity chamber and incubated at 37°C for 1.5 hours. Afterwards, coverslips were 
moved onto parafilm at room temperature and washed 3 times with PBS-Triton wash 
buffer with 50% blocking buffer for 5 minutes each wash. Secondary antibody mixture 
was prepared in 50% blocking buffer in PBS-Triton wash buffer, and 100 µL drops were 
placed on fresh parafilm, coverslips placed cell side down onto drops, and moved to a 
humidity chamber at 37°C for 1 hour. Humidity chamber was covered with aluminum 




chamber and placed cell side up on parafilm at room temperature. Cells were then 
washed for 5 minutes in PBS, followed by a 5-minute wash in Hanks Balanced Salt 
Solution (HBSS). Then nuclear stain was done for 20 minutes at room temperature in 
Hoechst (3 mL Hoechst in 5 mL HBSS) and covered in aluminum foil. Cells were then 
washed with HBSS for 5 minutes, followed by PBS for 5 minutes, and then with distilled 
water for 5 minutes. Coverslips were then mounted to slides and stored for imaging. 
Images were taken using a Leica inverted microscope (Leica CTR 6500 microscope). 
Images were quantified using ImageJ. 
4. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
RNA was extracted via Qiagen RNeasy Plus Mini Kit (Qiagen, #74136) as per 
manufacturer’s instructions. Nanodrop lite Spectrophotometer (Thermofisher) was used 
to calculate concentration and purity of RNA elution. Synthesis of cDNA was done via 
qScriptTM cDNA SuperMix Master Mix (Quantabio, #95048) as per manufacturer’s 
instructions. cDNA was stored at -20°C for short term storage and -80°C for long term 
storage for future use. The qRT-PCR experiment utilized SYBR Green detection with 
Fast SYBRTM Green Master Mix (ThermoFisher, #A25780), and reactions were run for 
40 cycles in 10 µL total. Analysis was completed using Viia7 Real-Time PCR System 
and software (Life Technologies). Samples were normalized to hGAPDH as an internal 
control. The primers used were as follows: 
hGAPDH forward  5’-GCACCGTCAAGGCTGAGAAC-3’ 
hGAPDH reverse  5’-GGATCTCGTCCTGGAAGATG-3’ 
hSpy1 forward  5’-TTGTGAGGAGGTTATGGCCATT-3’ 
hSpy1 reverse   5’-GCAGCTGAACTTCATCTCTGTTGTAG-3’ 




hMAP2 reverse  5’-CTTCCTCCACTGTGACAGTCTG-3’ 
5. Animal Care and Toxicity Screen 
WT zebrafish were handled in compliance with local animal care guidelines and standard 
protocols of Canada and following the animal utilization protocol #19-03. Adult zebrafish 
were kept at 28.5°C and bred according to “The Zebrafish Book” (Westerfield, 2000).  
 Eggs were collected and maintained in 28°C until 1dpf, where they were moved 
to 33°C and subsequent embryos were placed into 12-well plates at 8 embryos per well 
with E3 embryo media (5 mM NaCl, 0.17 mMKCl, 0.33 mM CaCl2, 0.33mM MgSO4, 
10–5% Methylene Blue). Starting at 3dpf, E3 media was replaced with E3 media 
containing either dinaciclib, NU2058, TMZ, or DMSO (dimethyl sulfoxide) at varying 
concentrations. Embryos were fed once at 4dpf, before new drug treatments began, for 30 
minutes until media was changed and drugs were added. Media was changed daily for 3 
consecutive days, before drug treatments began, and dead embryos were counted and 
removed each day. The sum of dead embryos was calculated 1 day after the last day of 
treatment (6dpf) and percentage of dead embryos was calculated. 
6. Zebrafish Injections 
Cells for zebrafish injections were fluorescently stained up to 2 hours before injection. 
Cells were washed with serum-free EMEM media and 0.25% trypsin was added for 5 
minutes to allow adherent cells to detach from plate. A total of 5x105 cells were collected 
and spun down at 1000 RPM for 5 minutes, media removed, and resuspended in 200 µL 
of serum-free media. Then 5 µL of VybrantTM DiO (green) (Invitrogen) dye was added to 
cell suspension and incubated at 37 °C for 20 minutes, with a quick and gentle vortex 




serum-free EMEM media, centrifuged again as above, and cells were resuspended in a 
final volume of 50 µL in serum-free EMEM media. 
 A 2% agarose gel was made in a 10 cm plate, and 0.168 mg/ml of Tricaine 
(Sigma, MS222) solution was prepared. A prepared needle was already pulled, and the 
day of injection was opened at the tip, placed into the Nanoject II microinjector 
(Drummond Scientific) and oil was taken up. Oil was then released partially, and cells 
were taken up into the needle. Embryos were anesthetized with tricaine before injection. 
Embryos were placed onto agarose gel and roughly 10 nL of cell suspension was injected 
into the yolk sac of embryos aged 2dpf. Successful injections were screened by imaging 
all injected fish next day with a Leica inverted microscope (Leica fluorescence 
stereomicroscope M205). Embryos were imaged at 35x magnification at the same 
exposure and intensity. Successfully injected embryos were separated and maintained in 
E3 media in 12-well plates at 8 embryos per well. Embryos were treated with dinaciclib 
or DMSO in E3 media daily for 3 days. Embryos were maintained at 28°C until 1dpf, and 
then moved to 33°C. 
7. Zebrafish Imaging and Analysis 
Embryos were imaged daily from 1 day post injection (1dpi) to 4dpi, and once at 7dpi. 
Embryos were anesthetized in tricaine and placed onto 2% agarose gel for imaging. A 
total of 4-5 embryos would be imaged at once, using a Leica fluorescent scope in the 
GFP channel. Images were imported into ImageJ, converted to 8-bit greyscale, and 
threshold was adjusted to eliminate background pixels. Threshold adjustments were kept 
the same for all images of all days. Labelled cells were measured as foci area under total 




area was normalized starting at the last day of treatment (3dpi), so each treatment group 
began with a normalized value of 1 on 3dpi. 
8. Brain and Tail Metastasis Analysis 
Images from 7dpi were used for analysis of metastases proximal to the brain. Foci were 
considered to be proximal to the brain if they were above/past the swim bladder towards 
the eyes, there was more than one foci away from the point of injection (yolk 
sac/intestines), and there was at least one foci in the area of the brain according to Figure 
1B (forebrain, midbrain, hindbrain). Foci were considered to be metastases down the tail 
if they were past the swim bladder away from the eyes and there was more than one foci 
away from the point of injection (yolk sac/intestines). Images from 3dpi embryos of 
MDA-MB-231 injected cells were obtained from Janice Tubman. These images were 
analyzed under the same conditions for both brain and tail metastases. 
9. Statistical Analysis 
GraphPad Prism 8.0.2 software was used for all statistical analysis except for matrix plots 
of drug combinations. Drug combination and synergy evaluation significance was 
completed using the Combenefit (Di Veroli et al., 2016) software, a one-sample Student’s 
t-test was performed to test significance of drug interaction. A one-way ANOVA was 
performed for number of nuclei, percent positive cells for antibodies Ki67, CD44, and 
CC-3 from Figure 5 B and C, and a Tukey’s multiple comparison test was performed 
from 5 different field of views (FOV) for each treatment. A one-way ANOVA was 
performed on qRT-PCR data from Figure 5E with a Tukey’s multiple comparison test 
from 3 separate experiments. Multiple t-tests using the Holm-Sidak method were 




8 fish per group per treatment. A one-way ANOVA was performed on percentage of fish 
with metastases proximal to the brain with a Tukey’s multiple comparison test from 2 
groups with 6-15 fish per group per treatment. A two-way ANOVA was performed on 
the comparison of metastases down the tail and proximal to the brain between the U87 

























1. Selected CKIs and Chemotherapeutics Have an Antagonistic Relationship 
Combination therapy consisting of two or more therapeutic agents is a widely used 
approach in the clinic. To achieve the desired and successful treatment results, drugs are 
combined to complete, fine-tune, and even enhance the action of one another. To 
determine the potential synergistic relationship between CKIs and commonly used 
chemotherapies, the EC50 was first determined for each drug. The GBM cell lines U87 
and U251 were used to determine the drug interactions of four different drugs, which 
include etoposide, TMZ, NU2058, and dinaciclib. EC50 values were determined using the 
cell viability MTT assay. All values and corresponding growth curves were calculated 
and produced using the free software, Combenefit (Di Veroli et al., 2016). Dinaciclib 
showed the strongest negative effect on cell viability and had the most consistent EC50 
values between the U87 and U251 cell lines at 11.2 nM and 13.7 nM, respectively 
(Figure 2A).  
 Using Combenefit and the synergy and antagonism model, Bliss independence 
model, matrix plots of synergy distribution and matrix plots along with the corresponding 
surface plots of synergy distribution were developed for U87 cells (Figure 3) and U251 
cells (Figure 4), respectively. The colour spectrum of the matrix plot presents antagonism 
increase, red marking high levels of antagonism, yellow marking slight antagonism, and 
green being an additive relationship. Alternatively, synergy increases as the colour 
spectrum moves from green to blue, darker blue being very synergistic and light blue 
being slightly synergistic. Values in the matrix plots represent the difference as a 




drugs, assuming there is no interaction between the two drugs. The results obtained for 
the U87 cell line show there was slight antagonism for most concentrations used between 
the drug combinations of NU2058 with etoposide and TMZ with dinaciclib (Figure 3). 
There was a marked increase in antagonism in the drug combination of etoposide with 
dinaciclib as dinaciclib concentration increased from 7.5 nM to 30 nM. The drug 
combination of NU2058 with TMZ showed mostly an additive effect of the two drugs in 
the different concentrations tested, however there was less significance within the matrix 
plot at each concentration combination. Data obtained for U251 cell line showed that 
every drug combination of a CKI with chemotherapy presented considerable antagonism 
(Figure 4). The values determined for the concentrations resulting in a more additive 
effect were found to be statistically not significant, unlike most antagonistic effects. 
Overall, the selected CKIs and chemotherapeutics used in combination had an 










Figure 2: EC50 values and inhibition curves of GBM cell lines.  
GBM cell lines were treated with either dinaciclib, TMZ, etoposide, or NU2058 daily for 
3 days, and cell viability was calculated via MTT assay. All EC50 values and graphs were 
calculated with Combenefit software. (A) Represents U251 cell line and (B) represents 
U87 (U87-MG) cell line. Interpolated EC50 values were calculated for TMZ and 
etoposide in (B) due to low data points. All data points are given as a mean of 3 separate 













Figure 3: U87 matrix plots of synergy distribution from combination of a CKI and 
chemotherapy. 
Matrix plots of synergy distribution from different drug combinations in the U87 cell 
line. Combinations included a CKI (dinaciclib or NU2058) and a chemotherapy (TMZ or 
etoposide). Cells were treated daily for 3 consecutive days. Values in each box of the 
matrix plot are given as an expected percentage difference from the additive effect of the 
2 drugs combined, ranging from -100 (antagonism) to 100 (synergy). *p<0.05, **p<0.01. 










Figure 4: U251 surface plots and the corresponding matrix plots of synergy 
distribution from combination of a CKI and chemotherapy. 
Surface plots (left) and the corresponding matrix plots (right) of drug combinations used 
for U251 cell line. Cells were treated for 3 consecutive days. Values in each box of the 
matrix plot are given as an expected percentage difference from the additive effect of the 
2 drugs combined, ranging from -100 (antagonism) to 100 (synergy). *p<0.05. Statistical 



















2. Dinaciclib Selects for a Stem-like Population of GBM Cells  
To analyze the post-treatment GBM cell populations, immunocytochemistry was 
performed utilizing U251 cells treated with dinaciclib, TMZ, or a combination of both. 
Cells were treated with 15 nM dinaciclib, or 50 µM TMZ, or a combination of both 
drugs. These values were slightly higher than the calculated EC50 values for U251 cells 
(11.2 nM for dinaciclib, 38.5 µM for TMZ). Cells were stained with antibodies for the 
proliferation marker Ki67, the stem-cell marker CD44, the apoptosis marker CC-3, and 
DAPI for nuclear staining. Slides were imaged (Figure 5A) and 5 images per slide were 
taken at the magnification of 20x and analyzed using ImageJ. Dinaciclib significantly 
decreased total number of nuclei per FOV, both as a single agent and in combination with 
TMZ, compared to the control, treated with an equivalent amount of DMSO, as well as to 
TMZ alone (Figure 5B). Next, the staining was quantified to determine the percent of 
positive cells for each antibody (Figure 5C). Dinaciclib significantly increased the 
number of cells positive for the proliferation marker Ki67 in the remaining post-treatment 
cell population, compared to control, and when used in combination with TMZ the 
proliferation marker was also significantly increased compared to the control and TMZ 
alone. A similar effect was observed for the stem cell marker CD44 expression. 
Dinaciclib significantly increased the amount of CD44+ cells when used alone or in 
combination with TMZ compared to both TMZ alone and the control. There was a 
significant increase of roughly 20% of cells positively staining for CC-3 observed in the 
dinaciclib/TMZ combination treatment compared to control. Analysis of the GBM post-





To further characterize and confirm the stemness of the remaining population 
after dinaciclib and TMZ combination treatment, cells were treated with vehicle control, 
dinaciclib, TMZ, or the combination of both at the same concentrations and conditions as 
above. Cells were collected and a qRT-PCR was conducted (Figure 5D). Results are 
given as log10 RQ (relative quantity) in comparison to the control. Dinaciclib and the 
combination of dinaciclib and TMZ caused significant increases in the GBM cell clonal 
expansion marker, SPDYA, coding for Spy1 protein, compared to TMZ treatment alone. 
MAP2 is a commonly used differentiation marker, responsible in cytoskeleton regulation 
in brain nerve cells. There is lower expression of MAP2 in gliomas compared to normal 
brain tissue (Zhou et al., 2015). There was also a significant decrease in MAP2 transcript 
levels of the combination treatment of dinaciclib and TMZ when compared to TMZ 
alone. Dinaciclib also caused a decrease in MAP2 transcript levels when compared to the 
control group and TMZ alone, although these results are not statistically significant 





















Figure 5: Dinaciclib decreases cell numbers and induces apoptosis in combination 
with TMZ.  
(A) Representative images from immunocytochemistry of U251 cells stained with DAPI 
and antibodies for CD44, Ki67, and CC-3. Cells were treated with either 50 µM of 
DMSO as vehicle control (CONTROL), 50 µM of TMZ, 15 nM of dinaciclib (DINA) or 
a combination of both (50 µM TMZ + 15 nM DINA). Images were taken at 100x oil and 
scale bars represent 40 µm. (B) Total number of nuclei from each group was quantified 
using images taken at 20x and ImageJ. Error bars represent standard error of the mean 
from 5 different images taken. ***p<0.001. Statistical significance calculated using a 
one-way ANOVA. (C) Percentage of cells positively stained for each antibody of Ki67, 
CD44, and CC-3. Total number of cells were counted using the same method as (B) and 
cells stained for each antibody was counted in the same method under Texas red filter 
image. Error bars represent standard error from 5 collected data points from 5 separate 
images. *p<0.05, **p<0.005, ***p<0.001. Statistical significance was calculated using a 
one-way ANOVA. (D) Schematic of CD44+ cells being isolated from dinaciclib 
treatment and mRNA levels tested with qRT-PCR. Image created with biorender.com. 









3. Total Foci are Reduced in vivo with Dinaciclib Treatment 
A schematic of the workflow for zebrafish injections is presented in Figure 6. Drugs 
tested in zebrafish embryos are shown in Table 1, and dinaciclib demonstrated the lowest 
amount of lethality and was therefore selected to be used. U87 cells were fluorescently 
labelled and injected into anesthetized embryos. Successfully injected embryos were 
treated with a high and a low concentration of dinaciclib, 75 nM and 7.5 nM, 
respectively. Images were taken daily of all embryos up until 7dpi (Figure 7A). Total foci 
area was measured using the raw integrated intensity from ImageJ analysis. Each group 
was then normalized to itself starting at 3dpi, the time when drug treatment ended. At 
4dpi there was a significant decrease of the foci area when the high concentration of 
dinaciclib was used, compared to the low concentration, but the decrease was not 
significant when compared to the DMSO treated control fish. However, at 7dpi, there was 
a significant decrease in foci area in the high concentration of dinaciclib compared to 
both the control and the low concentration of dinaciclib (Figure 7B). In summary, it was 
found that dinaciclib was less toxic to embryos and caused a decrease in total foci in vivo 













Figure 6: Schematic of zebrafish injections.  
(A) GBM cells were labelled with fluorescent dye and injected into anesthetized 
zebrafish embryos 2 days old. (B) Fish were placed in a 12-well plate at 8 fish per well. 
Fish were imaged and screened 24 hours after injection to select successfully injected fish 
to be subsequently moved to a new plate. (C) Drug treatments and vehicle control were 
added 24 hours after injection. (D) Images were taken using an inverted microscope 






Table 1: Drug viability in zebrafish embryos  
Treatment Concentration 
dinaciclib§ 25 nM 250 nM 1000 nM 
Total Embryos 50 50 50 
Embryos Alive 50 49 50 
% Death 0 2 0 
DMSO Vehicle Control * * * 
Total Embryos 50 50 50 
Embryos Alive 49 49 48 
% Death 2 2 4 
————————————————————————————————————— 
NU2058§ 25 µM 50 µM 100 µM 
Total Embryos 55 54 56 
Embryos Alive 35 33 2 
% Death 36.36 38.89 92.86 
DMSO Vehicle Control * * * 
Total Embryos 54 55 55 
Embryos Alive 51 54 53 
% Death 5.55 1.82 3.63 
————————————————————————————————————— 
TMZ† 40 µM 125 µM 250 µM 
Total Embryos 30 30 30 
Embryos Alive 30 29 30 
% Death 0 3.33 0 
DMSO Vehicle Control * * * 
Total Embryos N/A N/A 30 
Embryos Alive N/A N/A 27 
% Death N/A N/A 10 
* DMSO vehicle control was matched in dilution to media to corresponding drug 
treatment 
§ Result of 2 separate experiments 















Figure 7: Dinaciclib reduces relative tumour area.  
(A) Representative fluorescent and overlay images of zebrafish used for analysis. 
Embryos were anesthetized with Tricaine and injected with U87 cells. Scale bars equal 
500 µm. Top image represents a sham injected embryo. (B) Tumour area was measured 
at 3, 4, and 7dpi. Tumour area was normalized to 3dpi, the day treatments ended. 
Intensity of foci was measured using ImageJ. Error bars represent the standard error from 
2 groups, each group representing at least 6 fish. *p<0.05. Statistical significance was 



















4. Dinaciclib Reduces Metastases Proximal to the Brain 
Images taken at 7dpi were also analyzed for metastases proximal to the brain. Fish that 
had foci past the swim bladder, towards the eyes and away from the point of injection 
(yolk sac/intestines) and appeared to be near the brain (see Figure 1A) were quantified as 
fish with metastases proximal to brain. Figure 8A shows representative images from the 
DMSO vehicle control group with foci of U87 cells which were declared as fish with 
metastases proximal to the brain (red arrows). Each treatment group was measured this 
way and then total fish with metastases proximal to the brain were put into a percentage 
of the total amount of fish in that treatment group. Although there was no significance 
between groups, there is a trend of decreased metastasis towards the brain as dinaciclib 
concentration increases (Figure 8B). Images from the DMSO control group and no 
treatment (NT) group were then analyzed for total brain metastases and total tail 
metastases and then compared to untreated 3dpi embryos injected with breast cancer cells 
(MDA-MB-231). Tail metastases were measured by foci detected past the swim bladder 
(see Figure 1A). There were significantly more metastases proximal to the brain in fish 
injected with the U87 cell line, and a significant increase in tail metastases in fish injected 
with the MDA-MB-231 cell line (Figure 8C). Representative fluorescent and overlay 
image of a fish injected with U87 cells with tail metastases can be seen in Figure 8D. 
Although more work is needed as validation, it would appear the U87 cell line 




















Figure 8: Dinaciclib reduces metastasis towards the brain.  
(A) Representative fluorescent and overlay images of 7dpi zebrafish. U87 foci (red 
arrows) show metastasis in the vicinity of the midbrain and hindbrain. Both images are 
from the DMSO vehicle control group. Scale bars equals 500 µm. (B) Images were 
analyzed and put into categories of no metastases proximal to brain and metastases 
proximal to brain. There was no significance between groups according to a one-way 
ANOVA. NT = no treatment, DMSO = vehicle control, DINA = dinaciclib. Error bars 
represent the standard error from 2 groups, each group representing at least 6 fish. (C) All 
7dpi fish from NT and DMSO groups were analyzed for brain and tail metastases, and 
additional images of the breast cancer cell line MDA-MB-231 cells injected into the yolk 
sac were obtained from Janice Tubman and analyzed for brain and tail metastases. 
Images analyzed from Janice Tubman were taken at 3dpi. Error bars represent the 
standard of error from 2 groups, each group containing at least 16 fish. *p<0.05, 
**p<0.005. Statistical significance was calculated using a 2-way ANOVA. (D) 
Representative fluorescent and overlay images of 7dpi zebrafish injected with U87 cells. 
U87 foci (red arrowheads) show metastasis down the tail. Both images are from the 











Since the introduction of TMZ over a decade ago, the standard of care for patients with 
GBM has not been challenged to advance the clinical outcomes leaving patient survival 
rates in the same dismal position (Cantrell et al., 2019). It is therefore important to 
continue to explore new treatment and therapy options, including novel drugs and drug 
combinations, to improve survival rates and quality of life for patients with GBM.  
This study aimed to validate different combinations of CKIs and chemotherapy in 
the treatment of GBM in vitro. We found that all combinations of a CKI and 
chemotherapy tested caused high antagonism between the two drugs at most of the 
concentrations used in U251 cell line (Figure 4). The U87 cell line showed similar 
results, and although the combination of TMZ and NU2058 showed an overall additive 
effect, only 2 of the 9 matrix plots were tested significant, compared to 5 to 7 of 9 
significant matrix plots of all other matrix plots for U87 cell line (Figure 3). Additionally, 
there were two EC50 values (TMZ and etoposide) that were determined through 
interpolation in the U87 cell line. We recognize that these drugs barely cause 50% 
inhibition in the U87 cell line, and this demonstrates the high chemoresistance of GBM. 
This emphasizes the need for synergistic drug interactions in GBM treatment, especially 
because these interpolated results come from the currently used chemotherapies and not 
from the experimental CKIs. The observed antagonistic relationship could potentially 
result from the counteractive mechanisms of action of the drugs tested. The CKIs work 
by inhibiting CDKs and subsequently the cell cycle, stopping cells from dividing and 
growing (Hardcastle et al., 2004; Parry et al., 2010; Sedlacek, 2001). However, typical 




either directly or indirectly, leading to apoptosis (Chen, Chan, & Hsieh, 2013; 
Wilstermann et al., 2007; Wu et al., 2011; Zhang, Stevens, & Bradshaw, 2012). The 
timing of drug administration could be a major factor for the antagonism between a CKI 
and chemotherapy agent and should be further investigated. Recent work including 
bevacizumab, an angiogenesis inhibitor, addresses the issue of treatment timing in GBM 
patients in the clinic. Pasqualetti et al. showed that the timing of bevacizumab 
administration affected the median time of disease recurrence from the initial GBM 
diagnosis, from 9.9 months for early bevacizumab administration (after first line 
chemotherapy) to 13.1 months for delayed bevacizumab administration (after second- or 
third-line chemotherapy) (Pasqualetti et al., 2018). Although the overall survival rates 
were unchanged, this study shows that timing of bevacizumab administration may at least 
play a role in improving the quality of life for GBM patients. 
In terms of CKI and chemotherapy treatment, the timing could be critical 
depending on the specific characteristics of the combined drugs. For example, if a 
chemotherapy agent causes DNA damage at the end of G1 checkpoint or at mid S phase 
checkpoint, and a CKI causes a cell cycle stop at the G2/M checkpoint, it may be more 
beneficial to treat with the chemotherapy agent first. This would allow for DNA damage 
to accumulate, for the subsequently applied CKI, to stop the cell cycle at the end of DNA 
accumulation, allowing for more time to detect DNA damage and for activation of 
appropriate molecular signals toward apoptosis. Alternatively, if the chemotherapy agent 
causes DNA damage late in the cell cycle, it may be more beneficial to first treat with a 
CKI, which stops the cell cycle early, allowing the cells to synchronize, followed by 




result in optimizing the number of cells affected by the chemotherapy, increasing the 
cytotoxic effects and reducing chemoresistance.  
 Jane et al. showed that dinaciclib, in combination with Bcl-2/Bcl-xL inhibitors, 
significantly reduced GBM cell proliferation rates independent of p53 status, and there 
was little to no effect on cell population or apoptosis in the GBM cell line T98G when 
dinaciclib was combined with other chemotherapeutics, including TMZ and etoposide. 
However, a very high concentration of dinaciclib was used, at 1 µM, which is as much as 
1000 times higher than the calculated IC50 values for the inhibition of CDK2 and CDK5 
(1 nM). In addition, cells were only treated for 24 hours, limiting the time for cells to 
accumulate DNA damage and signal for apoptosis (Jane et al., 2016). These high 
concentrations of dinaciclib could be a factor in the results seen in combination 
treatments with other chemotherapeutics. It has been demonstrated recently that 
dinaciclib in low concentrations (5 nM), in combination with doxorubicin, enhanced 
senescence in the multiple myeloma cell line RPMI-8226 (Tang, Xu, Liang, & Gao, 
2018). The data presented by Jane et al. is consistent with this work; dinaciclib alone 
causes growth inhibition, but not cell death, in GBM cells. Our data show that cultures 
treated with dinaciclib alone and in combination with TMZ significantly reduced the total 
number of cells (Figure 5B). Furthermore, our study is the first to characterize the post- 
dinaciclib treatment cell populations. The remaining cells demonstrate more stem-like 
and aggressive character with elevated protein expression of stem-cell marker CD44 and 
proliferation marker Ki67, as well as increased transcript levels of BTIC expansion 
marker SPDYA and decreased transcript levels of the differentiation marker MAP2. These 




cell populations. This particular outcome of dinaciclib treatment could potentially serve 
as an important strategy for combination therapy as it selects BTIC population to be 
specifically targeted by another agent, limiting the expansion of the cells at the same 
time. Further work is needed, however, to determine the role of administration timing as 
well as potential agents to cooperate with the BTIC selective nature of dinaciclib. In 
summary, our and published data show that other parameters such as timing and 
mechanism of action along with drug concentration, play a pivotal role in the anticancer 
action of combined agents and should be carefully investigated while designing treatment 
regimens. 
 To address the effects of combination therapy in vivo, we utilized zebrafish 
xenograft and drug testing model. Despite several advantages of utilizing zebrafish there 
are many controversies about the model for cancer research. One large disadvantage in 
tumour transplantation using zebrafish is the temperature difference. Zebrafish embryos 
are maintained at 28°C, a large gap from the human body at 37°C. Most researchers 
compromise proper development of the embryo and optimal growth temperatures of the 
tumour cells, by exposing both embryos and xenografted cells to an “in-between” 
temperature, ranging from 32.5-35°C (Barriuso, Nagaraju, & Hurlstone, 2015; Cabezas-
Sainz et al., 2018; Kirchberger, Sturtzel, Pascoal, & Distel, 2017). A recent study by 
Cabezas-Sainz et al. suggests that injection and maintenance at 36°C optimizes cell 
growth and has no significant effect on the development of the embryo when compared to 
34°C (Cabezas-Sainz et al., 2018). Yan et al. also showed a transgenic zebrafish model 
that could maintain normal function at 37°C and could be xenografted with a large 




28°C upon collection for 1 day, where they were subsequently moved to 33°C for the 
remainder of the experiments.  
Additionally, zebrafish are not an ideal model for human diseases that take place 
in specific organs of the human body that zebrafish do not have, including prostate, 
breast, and lungs (Kirchberger, Sturtzel, Pascoal, & Distel, 2017). Despite those 
limitations, zebrafish offers cancer studies in a high-throughput manner, where human 
cells can be readily xenografted at certain immunocompromised stages of zebrafish 
development into an in vivo microenvironment (Greaves & Maley, 2012; Wertman, 
Veinotte, Dellaire, & Berman, 2016). Standard drug treatment of zebrafish embryos 
involves adding the drug to the water the embryos are in, which results in drugs taken up 
passively through the skin of the embryos (Kari, Rodeck, & Dicker, 2007). It is possible 
to measure the amount of drug absorbed by the zebrafish embryos using liquid 
chromatography-tandem mass spectrometry (Chen et al., 2017; Zhang, Qin, Zhang, & 
Hu, 2015). However, there is currently no way to measure the exact amount of drug being 
metabolized by zebrafish embryos.  
 Figure 6 is a graphical abstract of the method used in this thesis to inject and 
collect data from the zebrafish embryos. This method involved using groups of embryos 
in a larger well and analyzing the averages of the groups. It is not uncommon that other 
researchers look at each fish individually, and each method has its own advantages and 
disadvantages. When looking at each fish individually, each fish is placed in a single well 
of a 96-well plate creating a high-throughput study platform (Basnet, Zizioli, Taweedet, 
Finazzi, & Memo, 2019; Ferraiuolo, Tubman, Sinha, Hamm, & Porter, 2017; Lambert et 




embryo, which includes the small size of the well and feeding the fish in small confined 
space causing increased ammonia levels and an increased pH. In a smaller space these 
toxicities would theoretically accumulate faster due to the smaller volume of water. A 
major concern at this point is supplying the nutrition to the embryo but keeping them 
under consistent and not compromised environment during drug treatment. It is well 
established that the yolk is fully diminished by ~7dpf, and it is essential that the embryos 
are fed from this point on, but ideally 1-2 days before (Mathias, Saxena, & Mumm, 
2012). The time required for establishing tumour foci and tumour mass significantly 
exceeds that range of time, making it essential to keep the embryos fed. Using a 96-well 
plate to study zebrafish embryos individually is much more beneficial when comparing 
each fish individually over time during toxicity screens and for live imaging at the single 
cell level (White et al., 2008). When using zebrafish embryos for drug screening one can 
make the case for a larger well and pooling groups of embryos and averaging the results. 
By using a less stressful environment the embryos are healthier and subjected to more 
consistent environment with less possibility for an error.  
The potential toxic effects of two CKIs, dinaciclib and NU2058, were tested on 
zebrafish embryos. Dinaciclib was non-toxic in the embryos at concentrations as high as 
89-fold higher than the calculated EC50 values in the GBM cell lines used. 
Comparatively, NU2058 was extremely toxic to the embryos at concentrations close to 
the EC50 values, making it a poor drug to move forward with drug screening using 
zebrafish embryos (Table 1). NU2058 is an experimental drug not seen in recent 
literature, suggesting that the toxicity of this drug to animal models quickly eliminated it 




trials. When zebrafish embryos were injected with U87 cells and subsequently treated 
with dinaciclib, there was a significant decrease in foci area in high concentration (75 
nM) compared to vehicle control (DMSO) or low concentration (7.5 nM) after 4 days 
from the last treatment (Figure 7B). This would suggest that dinaciclib had successfully 
caused growth inhibition of injected U87 cells in the embryos, which is consistent with 
what is seen in vitro. The same embryo images were used in analysis of metastases of 
U87 cells (Figure 8). Although there were no significant differences seen (Figure 8B), 
there is a trend demonstrating that dinaciclib is reducing the total number of metastases 
towards the head. The limitations of this data are due to low replicate numbers (n=2), and 
future work would include the addition of more replicates as well as the addition of more 
GBM cell lines as well as patient-derived cell lines. Of the fish injected with U87 cells, 
the DMSO vehicle control and no treatment groups had a high percentage of fish with 
metastases proximal to the brain, but when analyzed for tail metastases, there were very 
few. Images of 3dpi embryos, injected with MDA-MB-231 cells (a breast cancer cell 
line), were obtained from Janice Tubman and analyzed the same way as the U87 cell 
injected embryos for brain and tail metastases. Interestingly there were no metastases 
proximal to the brain, but many down the tail (Figure 8C). This data would suggest that 
the human GBM cells are preferentially migrating towards the brain, confirming the 
validity of zebrafish as an animal model. The human MDA-MB-231 cells are a known 
invasive cell line, and there is evidence of those cells metastasizing throughout the 
zebrafish embryo once injected, including to the brain, eye, and tail, but no data on the 
amount of fish with specific metastases (Tulotta et al., 2016). There is also evidence of 




high as 70% of breast and prostate cancer patients with relapse develop bone metastases 
(Ibrahim, Mercatali, & Amadori, 2013; Mercatali et al., 2016; Roodman, 2004), and, as 
mentioned above, zebrafish lack specific organs that humans have, such as prostate, 
breast, and lungs (Kirchberger, Sturtzel, Pascoal, & Distel, 2017). The fact that the breast 
cancer cell line MDA-MB-231 tends to metastasize down the tail is interesting, and the 
lack of breasts within the zebrafish is of further interest. Future work would be needed to 
test this, for example, injecting zebrafish embryos with different types of human cancers, 
some with common organs (brain and liver), and some without (breast and prostate), and 
quantifying the amount of metastasis and localization of that metastasis. This experiment 
could solidify the use of zebrafish as an animal model for cancer, and potentially put 
some controversies to rest. This experiment would require sectioning and staining of 
zebrafish in order to confirm the localization of the transplanted cells. This highlights 
more future work required for this thesis, sectioning and staining injected zebrafish 
embryos to determine if the U87 cell line had in fact metastasized to the nervous tissue. 
In conclusion, this thesis has demonstrated that dinaciclib, in concurrent 
combination with a chemotherapy, is antagonistic in the GBM cell lines U87 and U251, 
and dinaciclib inhibits GBM cell growth and selects for the BTIC population in vitro. 
This advocates the potential use of dinaciclib in treatment of GBM, in combination with a 
treatment targeting the CD44+ BTIC population, and also addresses the question of the 









Agarwala, S. S., & Kirkwood, J. M. (2000). Temozolomide, a novel alkylating agent with 
activity in the central nervous system, may improve the treatment of advanced metastatic 
melanoma. The Oncologist, 5(2), 144–151. https://doi.org/10.1634/theoncologist.5-2-144 
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). 
Prospective identification of tumorigenic breast cancer cells. Proceedings of the National 
Academy of Sciences of the United States of America, 100(7), 3983–3988. 
https://doi.org/10.1073/pnas.0530291100 
Arellano, M., & Moreno, S. (1997). Regulation of CDK/cyclin complexes during the cell 
cycle. The International Journal of Biochemistry & Cell Biology, 29(4), 559–573. 
Arris, C. E., Boyle, F. T., Calvert, A. H., Curtin, N. J., Endicott, J. A., Garman, E. F., … Yu, 
W. (2000). Identification of novel purine and pyrimidine cyclin-dependent kinase 
inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. 
Journal of Medicinal Chemistry, 43(15), 2797–2804. https://doi.org/10.1021/jm990628o 
Asnani, A., & Peterson, R. T. (2014). The zebrafish as a tool to identify novel therapies for 
human cardiovascular disease. Disease Models & Mechanisms, 7(7), 763–767. 
https://doi.org/10.1242/dmm.016170 
Bailon-Moscoso, N., Cevallos-Solorzano, G., Romero-Benavides, J. C., & Orellana, M. I. R. 
(2017). Natural Compounds as Modulators of Cell Cycle Arrest: Application for 





Barnes, E. A., Porter, L. A., Lenormand, J.-L., Dellinger, R. W., & Donoghue, D. J. (2003). 
Human Spy1 promotes survival of mammalian cells following DNA damage. Cancer 
Research, 63(13), 3701–3707. 
Barriuso, J., Nagaraju, R., & Hurlstone, A. (2015). Zebrafish: A new companion for 
translational research in oncology. Clinical Cancer Research : An Official Journal of the 
American Association for Cancer Research, 21(5), 969–975. 
https://doi.org/10.1158/1078-0432.CCR-14-2921 
Basnet, R. M., Zizioli, D., Taweedet, S., Finazzi, D., & Memo, M. (2019). Zebrafish Larvae as 
a Behavioral Model in Neuropharmacology. Biomedicines, 7(1). 
https://doi.org/10.3390/biomedicines7010023 
Baumann, M., Krause, M., & Hill, R. (2008). Exploring the role of cancer stem cells in 
radioresistance. Nature Reviews. Cancer, 8(7), 545–554. https://doi.org/10.1038/nrc2419 
Begicevic, R.-R., & Falasca, M. (2017). ABC Transporters in Cancer Stem Cells: Beyond 
Chemoresistance. International Journal of Molecular Sciences, 18(11). 
https://doi.org/10.3390/ijms18112362 
Besson, A., Gurian-West, M., Schmidt, A., Hall, A., & Roberts, J. M. (2004). P27Kip1 
modulates cell migration through the regulation of RhoA activation. Genes & 
Development, 18(8), 862–876. https://doi.org/10.1101/gad.1185504 
Bliss, C. I. (1939). The Toxicity of Poisons Applied Jointly. Annals of Applied Biology, 26(3), 
585–615. https://doi.org/10.1111/j.1744-7348.1939.tb06990.x 
Bradshaw, A., Wickremesekera, A., Brasch, H. D., Chibnall, A. M., Davis, P. F., Tan, S. T., & 
Itinteang, T. (2016). Cancer Stem Cells in Glioblastoma Multiforme. Frontiers in 




Bronner, S. M., Merrick, K. A., Murray, J., Salphati, L., Moffat, J. G., Pang, J., … Heffron, T. 
P. (2019). Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma. Bioorganic & 
Medicinal Chemistry Letters, 29(16), 2294–2301. 
https://doi.org/10.1016/j.bmcl.2019.06.021 
Brown, D. V., Filiz, G., Daniel, P. M., Hollande, F., Dworkin, S., Amiridis, S., … 
Mantamadiotis, T. (2017). Expression of CD133 and CD44 in glioblastoma stem cells 
correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity. PloS 
One, 12(2), e0172791. https://doi.org/10.1371/journal.pone.0172791 
Bundgaard, M., & Abbott, N. J. (2008). All vertebrates started out with a glial blood-brain 
barrier 4-500 million years ago. Glia, 56(7), 699–708. https://doi.org/10.1002/glia.20642 
Cabezas-Sainz, P., Guerra-Varela, J., Carreira, M. J., Mariscal, J., Roel, M., Rubiolo, J. A., … 
Sanchez, L. (2018). Improving zebrafish embryo xenotransplantation conditions by 
increasing incubation temperature and establishing a proliferation index with ZFtool. 
BMC Cancer, 18(1), 3. https://doi.org/10.1186/s12885-017-3919-8 
Canepa, E. T., Scassa, M. E., Ceruti, J. M., Marazita, M. C., Carcagno, A. L., Sirkin, P. F., & 
Ogara, M. F. (2007). INK4 proteins, a family of mammalian CDK inhibitors with novel 
biological functions. IUBMB Life, 59(7), 419–426. 
https://doi.org/10.1080/15216540701488358 
Cantrell, J. N., Waddle, M. R., Rotman, M., Peterson, J. L., Ruiz-Garcia, H., Heckman, M. G., 
… Trifiletti, D. M. (2019). Progress Toward Long-Term Survivors of Glioblastoma. 





Cardoso, F. L., Brites, D., & Brito, M. A. (2010). Looking at the blood-brain barrier: 
Molecular anatomy and possible investigation approaches. Brain Research Reviews, 
64(2), 328–363. https://doi.org/10.1016/j.brainresrev.2010.05.003 
Carnero, A., & Hannon, G. J. (1998). The INK4 family of CDK inhibitors. Current Topics in 
Microbiology and Immunology, 227, 43–55. 
Carpentier, A., Canney, M., Vignot, A., Reina, V., Beccaria, K., Horodyckid, C., … Idbaih, A. 
(2016). Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Science 
Translational Medicine, 8(343), 343re2. https://doi.org/10.1126/scitranslmed.aaf6086 
Chen, B., Gao, Z.-Q., Liu, Y., Zheng, Y.-M., Han, Y., Zhang, J.-P., & Hu, C.-Q. (2017). 
Embryo and Developmental Toxicity of Cefazolin Sodium Impurities in Zebrafish. 
Frontiers in Pharmacology, 8, 403. https://doi.org/10.3389/fphar.2017.00403 
Chen, S. H., Chan, N.-L., & Hsieh, T. (2013). New mechanistic and functional insights into 
DNA topoisomerases. Annual Review of Biochemistry, 82, 139–170. 
https://doi.org/10.1146/annurev-biochem-061809-100002 
Cheng, C. K., Gustafson, W. C., Charron, E., Houseman, B. T., Zunder, E., Goga, A., … Fan, 
Q.-W. (2012). Dual blockade of lipid and cyclin-dependent kinases induces synthetic 
lethality in malignant glioma. Proceedings of the National Academy of Sciences of the 
United States of America, 109(31), 12722–12727. 
https://doi.org/10.1073/pnas.1202492109 
Cheung, Z. H., & Ip, N. Y. (2012). Cdk5: A multifaceted kinase in neurodegenerative 





Chi, N. C., Shaw, R. M., Jungblut, B., Huisken, J., Ferrer, T., Arnaout, R., … Stainier, D. Y. 
R. (2008). Genetic and physiologic dissection of the vertebrate cardiac conduction 
system. PLoS Biology, 6(5), e109. https://doi.org/10.1371/journal.pbio.0060109 
Chou, T. C., & Talalay, P. (1977). A simple generalized equation for the analysis of multiple 
inhibitions of Michaelis-Menten kinetic systems. The Journal of Biological Chemistry, 
252(18), 6438–6442. 
Comprehensive genomic characterization defines human glioblastoma genes and 
core pathways. (2008). Nature, 455(7216), 1061–1068. 
https://doi.org/10.1038/nature07385 
Coqueret, O. (2003). New roles for p21 and p27 cell-cycle inhibitors: A function for each cell 
compartment? Trends in Cell Biology, 13(2), 65–70. 
Di Veroli, G. Y., Fornari, C., Wang, D., Mollard, S., Bramhall, J. L., Richards, F. M., & 
Jodrell, D. I. (2016). Combenefit: An interactive platform for the analysis and 
visualization of drug combinations. Bioinformatics (Oxford, England), 32(18), 2866–
2868. https://doi.org/10.1093/bioinformatics/btw230 
Domb, A. J., Rock, M., Perkin, C., Yipchuck, G., Broxup, B., & Villemure, J. G. (1995). 
Excretion of a radiolabelled anticancer biodegradable polymeric implant from the rabbit 
brain. Biomaterials, 16(14), 1069–1072. https://doi.org/10.1016/0142-9612(95)98902-q 
Eagan, R. T., Carr, D. T., Frytak, S., Rubin, J., & Lee, R. E. (1976). VP-16-213 versus 
polychemotherapy in patients with advanced small cell lung cancer. Cancer Treatment 




Einhorn, L. H. (1990). Treatment of testicular cancer: A new and improved model. Journal of 
Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 8(11), 
1777–1781. https://doi.org/10.1200/JCO.1990.8.11.1777 
Evans, A., Scher, C., & D’Angio, G. (1992). Treatment of advanced neuroblastoma. European 
Journal of Cancer (Oxford, England : 1990), 28A(8–9), 1301–1302. 
https://doi.org/10.1016/0959-8049(92)90502-s 
Eyler, C. E., & Rich, J. N. (2008). Survival of the fittest: Cancer stem cells in therapeutic 
resistance and angiogenesis. Journal of Clinical Oncology : Official Journal of the 
American Society of Clinical Oncology, 26(17), 2839–2845. 
https://doi.org/10.1200/JCO.2007.15.1829 
Ferby, I., Blazquez, M., Palmer, A., Eritja, R., & Nebreda, A. R. (1999). A novel p34(cdc2)-
binding and activating protein that is necessary and sufficient to trigger G(2)/M 
progression in Xenopus oocytes. Genes & Development, 13(16), 2177–2189. 
https://doi.org/10.1101/gad.13.16.2177 
Ferraiuolo, R.-M., Tubman, J., Sinha, I., Hamm, C., & Porter, L. A. (2017). The cyclin-like 
protein, SPY1, regulates the ERalpha and ERK1/2 pathways promoting tamoxifen 
resistance. Oncotarget, 8(14), 23337–23352. https://doi.org/10.18632/oncotarget.15578 
Firestein, R., Bass, A. J., Kim, S. Y., Dunn, I. F., Silver, S. J., Guney, I., … Hahn, W. C. 
(2008). CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. 
Nature, 455(7212), 547–551. https://doi.org/10.1038/nature07179 
Fleming, A., Diekmann, H., & Goldsmith, P. (2013). Functional characterisation of the 





Foucquier, J., & Guedj, M. (2015). Analysis of drug combinations: Current methodological 
landscape. Pharmacology Research & Perspectives, 3(3), e00149. 
https://doi.org/10.1002/prp2.149 
Ghotra, V. P. S., He, S., de Bont, H., van der Ent, W., Spaink, H. P., van de Water, B., … 
Danen, E. H. J. (2012). Automated whole animal bio-imaging assay for human cancer 
dissemination. PloS One, 7(2), e31281. https://doi.org/10.1371/journal.pone.0031281 
Gibert, Y., Trengove, M. C., & Ward, A. C. (2013). Zebrafish as a genetic model in pre-
clinical drug testing and screening. Current Medicinal Chemistry, 20(19), 2458–2466. 
https://doi.org/10.2174/0929867311320190005 
Gilbert, M. R., Friedman, H. S., Kuttesch, J. F., Prados, M. D., Olson, J. J., Reaman, G. H., & 
Zaknoen, S. L. (2002). A phase II study of temozolomide in patients with newly 
diagnosed supratentorial malignant glioma before radiation therapy. Neuro-Oncology, 
4(4), 261–267. https://doi.org/10.1093/neuonc/4.4.261 
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., … Mehta, M. 
P. (2013). Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized 
phase III clinical trial. Journal of Clinical Oncology : Official Journal of the American 
Society of Clinical Oncology, 31(32), 4085–4091. 
https://doi.org/10.1200/JCO.2013.49.6968 
Girard, F., Strausfeld, U., Fernandez, A., & Lamb, N. J. (1991). Cyclin A is required for the 
onset of DNA replication in mammalian fibroblasts. Cell, 67(6), 1169–1179. 
https://doi.org/10.1016/0092-8674(91)90293-8 
Goldstone, J. V., McArthur, A. G., Kubota, A., Zanette, J., Parente, T., Jonsson, M. E., … 




complement of Cytochrome P450 genes in Zebrafish. BMC Genomics, 11, 643. 
https://doi.org/10.1186/1471-2164-11-643 
Greaves, M., & Maley, C. C. (2012). Clonal evolution in cancer. Nature, 481(7381), 306–313. 
https://doi.org/10.1038/nature10762 
Greco, W. R., Bravo, G., & Parsons, J. C. (1995). The search for synergy: A critical review 
from a response surface perspective. Pharmacological Reviews, 47(2), 331–385. 
Groothuis, D. R. (2000). The blood-brain and blood-tumor barriers: A review of strategies for 
increasing drug delivery. Neuro-Oncology, 2(1), 45–59. 
https://doi.org/10.1093/neuonc/2.1.45 
Haldi, M., Ton, C., Seng, W. L., & McGrath, P. (2006). Human melanoma cells transplanted 
into zebrafish proliferate, migrate, produce melanin, form masses and stimulate 
angiogenesis in zebrafish. Angiogenesis, 9(3), 139–151. https://doi.org/10.1007/s10456-
006-9040-2 
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 
144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013 
Hardcastle, I. R., Arris, C. E., Bentley, J., Boyle, F. T., Chen, Y., Curtin, N. J., … Whitfield, 
H. J. (2004). N2-substituted O6-cyclohexylmethylguanine derivatives: Potent inhibitors 
of cyclin-dependent kinases 1 and 2. Journal of Medicinal Chemistry, 47(15), 3710–
3722. https://doi.org/10.1021/jm0311442 
Harper, J. W., Elledge, S. J., Keyomarsi, K., Dynlacht, B., Tsai, L. H., Zhang, P., … Swindell, 
E. (1995). Inhibition of cyclin-dependent kinases by p21. Molecular Biology of the Cell, 




Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., … Stupp, 
R. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. The 
New England Journal of Medicine, 352(10), 997–1003. 
https://doi.org/10.1056/NEJMoa043331 
Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M., Geschwind, D. H., 
Bronner-Fraser, M., & Kornblum, H. I. (2003). Cancerous stem cells can arise from 
pediatric brain tumors. Proceedings of the National Academy of Sciences of the United 
States of America, 100(25), 15178–15183. https://doi.org/10.1073/pnas.2036535100 
Hengst, L., & Reed, S. I. (1998). Inhibitors of the Cip/Kip family. Current Topics in 
Microbiology and Immunology, 227, 25–41. 
Higginbottom, K., Cummings, M., Newland, A. C., & Allen, P. D. (2002). Etoposide-
mediated deregulation of the G2M checkpoint in myeloid leukaemic cell lines results in 
loss of cell survival. British Journal of Haematology, 119(4), 956–964. 
https://doi.org/10.1046/j.1365-2141.2002.03977.x 
Howe, K., Clark, M. D., Torroja, C. F., Torrance, J., Berthelot, C., Muffato, M., … Stemple, 
D. L. (2013). The zebrafish reference genome sequence and its relationship to the human 
genome. Nature, 496(7446), 498–503. https://doi.org/10.1038/nature12111 
Ibrahim, T., Mercatali, L., & Amadori, D. (2013). A new emergency in oncology: Bone 
metastases in breast cancer patients (Review). Oncology Letters, 6(2), 306–310. 
https://doi.org/10.3892/ol.2013.1372 
Iorns, E., Turner, N. C., Elliott, R., Syed, N., Garrone, O., Gasco, M., … Ashworth, A. (2008). 
Identification of CDK10 as an important determinant of resistance to endocrine therapy 




Jane, E. P., Premkumar, D. R., Cavaleri, J. M., Sutera, P. A., Rajasekar, T., & Pollack, I. F. 
(2016). Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal 
Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human 
Glioma Cell Lines. The Journal of Pharmacology and Experimental Therapeutics, 
356(2), 354–365. https://doi.org/10.1124/jpet.115.230052 
Jia, Jia, Zhu, F., Ma, X., Cao, Z., Cao, Z. W., Li, Y., … Chen, Y. Z. (2009). Mechanisms of 
drug combinations: Interaction and network perspectives. Nature Reviews. Drug 
Discovery, 8(2), 111–128. https://doi.org/10.1038/nrd2683 
Jia, Jianwu, Wang, J., Yin, M., & Liu, Y. (2019). MicroRNA-605 directly targets SOX9 to 
alleviate the aggressive phenotypes of glioblastoma multiforme cell lines by deactivating 
the PI3K/Akt pathway. OncoTargets and Therapy, 12, 5437–5448. 
https://doi.org/10.2147/OTT.S213026 
Johansen, A., Hansen, H. D., Svarer, C., Lehel, S., Leth-Petersen, S., Kristensen, J. L., … 
Knudsen, G. M. (2018). The importance of small polar radiometabolites in molecular 
neuroimaging: A PET study with [(11)C]Cimbi-36 labeled in two positions. Journal of 
Cerebral Blood Flow and Metabolism : Official Journal of the International Society of 
Cerebral Blood Flow and Metabolism, 38(4), 659–668. 
https://doi.org/10.1177/0271678X17746179 
Johansson, M., & Persson, J. L. (2008). Cancer therapy: Targeting cell cycle regulators. Anti-
Cancer Agents in Medicinal Chemistry, 8(7), 723–731. 
Kari, G., Rodeck, U., & Dicker, A. P. (2007). Zebrafish: An emerging model system for 





Kastan, M. B., & Bartek, J. (2004). Cell-cycle checkpoints and cancer. Nature, 432(7015), 
316–323. https://doi.org/10.1038/nature03097 
Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., … 
Sausville, E. (1992). Growth inhibition with reversible cell cycle arrest of carcinoma cells 
by flavone. Journal of the National Cancer Institute, 84(22), 1736–1740. 
https://doi.org/10.1093/jnci/84.22.1736 
Kim, E. S. (2017). Abemaciclib: First Global Approval. Drugs, 77(18), 2063–2070. 
https://doi.org/10.1007/s40265-017-0840-z 
Kim, W. Y., & Sharpless, N. E. (2006). The regulation of INK4/ARF in cancer and aging. 
Cell, 127(2), 265–275. https://doi.org/10.1016/j.cell.2006.10.003 
Kirchberger, S., Sturtzel, C., Pascoal, S., & Distel, M. (2017). Quo natas, Danio?-Recent 
Progress in Modeling Cancer in Zebrafish. Frontiers in Oncology, 7, 186. 
https://doi.org/10.3389/fonc.2017.00186 
Kolenda, J., Jensen, S. S., Aaberg-Jessen, C., Christensen, K., Andersen, C., Brunner, N., & 
Kristensen, B. W. (2011). Effects of hypoxia on expression of a panel of stem cell and 
chemoresistance markers in glioblastoma-derived spheroids. Journal of Neuro-Oncology, 
103(1), 43–58. https://doi.org/10.1007/s11060-010-0357-8 
Konantz, M., Balci, T. B., Hartwig, U. F., Dellaire, G., Andre, M. C., Berman, J. N., & 
Lengerke, C. (2012). Zebrafish xenografts as a tool for in vivo studies on human cancer. 
Annals of the New York Academy of Sciences, 1266, 124–137. 
https://doi.org/10.1111/j.1749-6632.2012.06575.x 
Kreso, A., & Dick, J. E. (2014). Evolution of the cancer stem cell model. Cell Stem Cell, 




Lam, S. H., Chua, H. L., Gong, Z., Lam, T. J., & Sin, Y. M. (2004). Development and 
maturation of the immune system in zebrafish, Danio rerio: A gene expression profiling, 
in situ hybridization and immunological study. Developmental and Comparative 
Immunology, 28(1), 9–28. 
Lambert, C. J., Freshner, B. C., Chung, A., Stevenson, T. J., Bowles, D. M., Samuel, R., … 
Bonkowsky, J. L. (2018). An automated system for rapid cellular extraction from live 
zebrafish embryos and larvae: Development and application to genotyping. PloS One, 
13(3), e0193180. https://doi.org/10.1371/journal.pone.0193180 
Lampreht Tratar, U., Horvat, S., & Cemazar, M. (2018). Transgenic Mouse Models in Cancer 
Research. Frontiers in Oncology, 8, 268. https://doi.org/10.3389/fonc.2018.00268 
Lee, L. M. J., Seftor, E. A., Bonde, G., Cornell, R. A., & Hendrix, M. J. C. (2005). The fate of 
human malignant melanoma cells transplanted into zebrafish embryos: Assessment of 
migration and cell division in the absence of tumor formation. Developmental Dynamics : 
An Official Publication of the American Association of Anatomists, 233(4), 1560–1570. 
https://doi.org/10.1002/dvdy.20471 
Lee, M. H., Reynisdottir, I., & Massague, J. (1995). Cloning of p57KIP2, a cyclin-dependent 
kinase inhibitor with unique domain structure and tissue distribution. Genes & 
Development, 9(6), 639–649. https://doi.org/10.1101/gad.9.6.639 
Lenormand, J. L., Dellinger, R. W., Knudsen, K. E., Subramani, S., & Donoghue, D. J. (1999). 





Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., … Simeone, D. M. 
(2007). Identification of pancreatic cancer stem cells. Cancer Research, 67(3), 1030–
1037. https://doi.org/10.1158/0008-5472.CAN-06-2030 
Li, J., Qian, W.-P., & Sun, Q.-Y. (2019). Cyclins regulating oocyte meiotic cell cycle 
progression. Biology of Reproduction. https://doi.org/10.1093/biolre/ioz143 
Liebner, S., Czupalla, C. J., & Wolburg, H. (2011). Current concepts of blood-brain barrier 
development. The International Journal of Developmental Biology, 55(4–5), 467–476. 
https://doi.org/10.1387/ijdb.103224sl 
Lieschke, G. J., & Trede, N. S. (2009). Fish immunology. Current Biology : CB, 19(16), 
R678-682. https://doi.org/10.1016/j.cub.2009.06.068 
Lim, S., & Kaldis, P. (2013). Cdks, cyclins and CKIs: Roles beyond cell cycle regulation. 
Development (Cambridge, England), 140(15), 3079–3093. 
https://doi.org/10.1242/dev.091744 
Liu, L., Michowski, W., Inuzuka, H., Shimizu, K., Nihira, N. T., Chick, J. M., … Sicinski, P. 
(2017). G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem 
cells. Nature Cell Biology, 19(3), 177–188. https://doi.org/10.1038/ncb3474 
Loewe, S. (1928). Die quantitativen Probleme der Pharmakologie. Ergebnisse Der 
Physiologie, 27(1), 47–187. https://doi.org/10.1007/BF02322290 
Lotsch, J., & Geisslinger, G. (2011). Low-dose drug combinations along molecular pathways 
could maximize therapeutic effectiveness while minimizing collateral adverse effects. 





Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, 
W. K., … Ellison, D. W. (2016). The 2016 World Health Organization Classification of 
Tumors of the Central Nervous System: A summary. Acta Neuropathologica, 131(6), 
803–820. https://doi.org/10.1007/s00401-016-1545-1 
Lubanska, D., Market-Velker, B. A., deCarvalho, A. C., Mikkelsen, T., Fidalgo da Silva, E., & 
Porter, L. A. (2014). The cyclin-like protein Spy1 regulates growth and division 
characteristics of the CD133+ population in human glioma. Cancer Cell, 25(1), 64–76. 
https://doi.org/10.1016/j.ccr.2013.12.006 
Lubanska, D., & Porter, L. (2017). Revisiting CDK Inhibitors for Treatment of Glioblastoma 
Multiforme. Drugs in R&D, 17(2), 255–263. https://doi.org/10.1007/s40268-017-0180-1 
MacRae, C. A., & Peterson, R. T. (2015). Zebrafish as tools for drug discovery. Nature 
Reviews. Drug Discovery, 14(10), 721–731. https://doi.org/10.1038/nrd4627 
Martin, M. P., Olesen, S. H., Georg, G. I., & Schonbrunn, E. (2013). Cyclin-dependent kinase 
inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. 
ACS Chemical Biology, 8(11), 2360–2365. https://doi.org/10.1021/cb4003283 
Mathias, J. R., Saxena, M. T., & Mumm, J. S. (2012). Advances in zebrafish chemical 
screening technologies. Future Medicinal Chemistry, 4(14), 1811–1822. 
https://doi.org/10.4155/fmc.12.115 
Meijer, A. H., & Spaink, H. P. (2011). Host-pathogen interactions made transparent with the 
zebrafish model. Current Drug Targets, 12(7), 1000–1017. 
https://doi.org/10.2174/138945011795677809 
Mercatali, L., La Manna, F., Groenewoud, A., Casadei, R., Recine, F., Miserocchi, G., … 




Cancer Bone Metastasis in a Zebrafish Model. International Journal of Molecular 
Sciences, 17(8). https://doi.org/10.3390/ijms17081375 
Minniti, G., Muni, R., Lanzetta, G., Marchetti, P., & Enrici, R. M. (2009). Chemotherapy for 
glioblastoma: Current treatment and future perspectives for cytotoxic and targeted agents. 
Anticancer Research, 29(12), 5171–5184. 
Molenaar, J. J., Ebus, M. E., Geerts, D., Koster, J., Lamers, F., Valentijn, L. J., … Caron, H. 
N. (2009). Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer 
cells. Proceedings of the National Academy of Sciences of the United States of America, 
106(31), 12968–12973. https://doi.org/10.1073/pnas.0901418106 
Morikawa, A., & Henry, N. L. (2015). Palbociclib for the Treatment of Estrogen Receptor-
Positive, HER2-Negative Metastatic Breast Cancer. Clinical Cancer Research : An 
Official Journal of the American Association for Cancer Research, 21(16), 3591–3596. 
https://doi.org/10.1158/1078-0432.CCR-15-0390 
Mullard, A. (2017). FDA approves Novartis’s CDK4/6 inhibitor. Nature Reviews. Drug 
Discovery, 16(4), 229. https://doi.org/10.1038/nrd.2017.62 
Mullins, M. C., Hammerschmidt, M., Haffter, P., & Nusslein-Volhard, C. (1994). Large-scale 
mutagenesis in the zebrafish: In search of genes controlling development in a vertebrate. 
Current Biology : CB, 4(3), 189–202. https://doi.org/10.1016/s0960-9822(00)00048-8 
Nam, C., Doi, K., & Nakayama, H. (2010). Etoposide induces G2/M arrest and apoptosis in 
neural progenitor cells via DNA damage and an ATM/p53-related pathway. Histology 
and Histopathology, 25(4), 485–493. https://doi.org/10.14670/HH-25.485 
Nemunaitis, J. J., Small, K. A., Kirschmeier, P., Zhang, D., Zhu, Y., Jou, Y.-M., … Bannerji, 




dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. 
Journal of Translational Medicine, 11, 259. https://doi.org/10.1186/1479-5876-11-259 
Norbury, C., & Nurse, P. (1992). Animal cell cycles and their control. Annual Review of 
Biochemistry, 61, 441–470. https://doi.org/10.1146/annurev.bi.61.070192.002301 
O’Brown, N. M., Pfau, S. J., & Gu, C. (2018). Bridging barriers: A comparative look at the 
blood-brain barrier across organisms. Genes & Development, 32(7–8), 466–478. 
https://doi.org/10.1101/gad.309823.117 
Ohtsubo, M., Theodoras, A. M., Schumacher, J., Roberts, J. M., & Pagano, M. (1995). Human 
cyclin E, a nuclear protein essential for the G1-to-S phase transition. Molecular and 
Cellular Biology, 15(5), 2612–2624. https://doi.org/10.1128/mcb.15.5.2612 
Ortega, S., Malumbres, M., & Barbacid, M. (2002). Cyclin D-dependent kinases, INK4 
inhibitors and cancer. Biochimica et Biophysica Acta, 1602(1), 73–87. 
https://doi.org/10.1016/s0304-419x(02)00037-9 
Otto, T., & Sicinski, P. (2017). Cell cycle proteins as promising targets in cancer therapy. 
Nature Reviews. Cancer, 17(2), 93–115. https://doi.org/10.1038/nrc.2016.138 
Pardridge, W. M. (2005). The blood-brain barrier: Bottleneck in brain drug development. 
NeuroRx : The Journal of the American Society for Experimental NeuroTherapeutics, 
2(1), 3–14. https://doi.org/10.1602/neurorx.2.1.3 
Pardridge, W. M. (2009). Alzheimer’s disease drug development and the problem of the 
blood-brain barrier. Alzheimer’s & Dementia : The Journal of the Alzheimer’s 
Association, 5(5), 427–432. https://doi.org/10.1016/j.jalz.2009.06.003 
Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., … Lees, E. M. 




Molecular Cancer Therapeutics, 9(8), 2344–2353. https://doi.org/10.1158/1535-
7163.MCT-10-0324 
Pasqualetti, F., Gonnelli, A., Molinari, A., Cantarella, M., Montrone, S., Cristaudo, A., … 
Paiar, F. (2018). Different Timing to Use Bevacizumab in Patients with Recurrent 
Glioblastoma: Early Versus Delayed Administration. Anticancer Research, 38(10), 
5877–5881. https://doi.org/10.21873/anticanres.12930 
Pemovska, T., Bigenzahn, J. W., & Superti-Furga, G. (2018). Recent advances in 
combinatorial drug screening and synergy scoring. Current Opinion in Pharmacology, 
42, 102–110. https://doi.org/10.1016/j.coph.2018.07.008 
Polyak, K., Lee, M. H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & 
Massague, J. (1994). Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a 
potential mediator of extracellular antimitogenic signals. Cell, 78(1), 59–66. 
https://doi.org/10.1016/0092-8674(94)90572-x 
Porter, L. A., Dellinger, R. W., Tynan, J. A., Barnes, E. A., Kong, M., Lenormand, J.-L., & 
Donoghue, D. J. (2002). Human Speedy: A novel cell cycle regulator that enhances 
proliferation through activation of Cdk2. The Journal of Cell Biology, 157(3), 357–366. 
https://doi.org/10.1083/jcb.200109045 
Quintavalle, M., Elia, L., Price, J. H., Heynen-Genel, S., & Courtneidge, S. A. (2011). A cell-
based high-content screening assay reveals activators and inhibitors of cancer cell 
invasion. Science Signaling, 4(183), ra49. https://doi.org/10.1126/scisignal.2002032 
Rahman, R., Hempfling, K., Norden, A. D., Reardon, D. A., Nayak, L., Rinne, M. L., … Lee, 




recurrent glioblastoma patients who have failed prior bevacizumab. Neuro-Oncology, 
16(11), 1523–1529. https://doi.org/10.1093/neuonc/nou118 
Rello-Varona, S., Fuentes-Guirado, M., Lopez-Alemany, R., Contreras-Perez, A., Mulet-
Margalef, N., Garcia-Monclus, S., … Garcia Del Muro, X. (2019). Bcl-xL inhibition 
enhances Dinaciclib-induced cell death in soft-tissue sarcomas. Scientific Reports, 9(1), 
3816. https://doi.org/10.1038/s41598-019-40106-7 
Rigas, A. C., Robson, C. N., & Curtin, N. J. (2007). Therapeutic potential of CDK inhibitor 
NU2058 in androgen-independent prostate cancer. Oncogene, 26(55), 7611–7619. 
https://doi.org/10.1038/sj.onc.1210586 
Roel, M., Rubiolo, J. A., Guerra-Varela, J., Silva, S. B. L., Thomas, O. P., Cabezas-Sainz, P., 
… Botana, L. M. (2016). Marine guanidine alkaloids crambescidins inhibit tumor growth 
and activate intrinsic apoptotic signaling inducing tumor regression in a colorectal 
carcinoma zebrafish xenograft model. Oncotarget, 7(50), 83071–83087. 
https://doi.org/10.18632/oncotarget.13068 
Roodman, G. D. (2004). Mechanisms of bone metastasis. The New England Journal of 
Medicine, 350(16), 1655–1664. https://doi.org/10.1056/NEJMra030831 
Roskoski, R. J. (2019). Cyclin-dependent protein serine/threonine kinase inhibitors as 
anticancer drugs. Pharmacological Research, 139, 471–488. 
https://doi.org/10.1016/j.phrs.2018.11.035 
Roussel, M. F. (1999). The INK4 family of cell cycle inhibitors in cancer. Oncogene, 18(38), 
5311–5317. https://doi.org/10.1038/sj.onc.1202998 
Sedlacek, H. H. (2001). Mechanisms of action of flavopiridol. Critical Reviews in 




Seliger, C., & Hau, P. (2018). Drug Repurposing of Metabolic Agents in Malignant Glioma. 
International Journal of Molecular Sciences, 19(9). 
https://doi.org/10.3390/ijms19092768 
Senbanjo, L. T., & Chellaiah, M. A. (2017). CD44: A Multifunctional Cell Surface Adhesion 
Receptor Is a Regulator of Progression and Metastasis of Cancer Cells. Frontiers in Cell 
and Developmental Biology, 5, 18. https://doi.org/10.3389/fcell.2017.00018 
Shapira-Furman, T., Serra, R., Gorelick, N., Doglioli, M., Tagliaferri, V., Cecia, A., … Domb, 
A. J. (2019). Biodegradable wafers releasing Temozolomide and Carmustine for the 
treatment of brain cancer. Journal of Controlled Release : Official Journal of the 
Controlled Release Society, 295, 93–101. https://doi.org/10.1016/j.jconrel.2018.12.048 
Sharma, P. S., Sharma, R., & Tyagi, R. (2008). Inhibitors of cyclin dependent kinases: Useful 
targets for cancer treatment. Current Cancer Drug Targets, 8(1), 53–75. 
Shen, S., Dean, D. C., Yu, Z., & Duan, Z. (2019). Role of cyclin-dependent kinases (CDKs) in 
hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway. 
Hepatology Research : The Official Journal of the Japan Society of Hepatology. 
https://doi.org/10.1111/hepr.13353 
Sherr, C. J. (1994). G1 phase progression: Cycling on cue. Cell, 79(4), 551–555. 
https://doi.org/10.1016/0092-8674(94)90540-1 
Sherr, C. J., & Roberts, J. M. (1999). CDK inhibitors: Positive and negative regulators of G1-





Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., … Dirks, P. B. 
(2004). Identification of human brain tumour initiating cells. Nature, 432(7015), 396–
401. https://doi.org/10.1038/nature03128 
Spiro, Z., Kovacs, I. A., & Csermely, P. (2008). Drug-therapy networks and the prediction of 
novel drug targets. Journal of Biology, 7(6), 20. https://doi.org/10.1186/jbiol81 
Spitsbergen, J. (2007). Imaging neoplasia in zebrafish. Nature Methods, 4(7), 548–549. 
https://doi.org/10.1038/nmeth0707-548 
Stamatovic, S. M., Keep, R. F., & Andjelkovic, A. V. (2008). Brain endothelial cell-cell 
junctions: How to “open” the blood brain barrier. Current Neuropharmacology, 6(3), 
179–192. https://doi.org/10.2174/157015908785777210 
Stoletov, K., Montel, V., Lester, R. D., Gonias, S. L., & Klemke, R. (2007). High-resolution 
imaging of the dynamic tumor cell vascular interface in transparent zebrafish. 
Proceedings of the National Academy of Sciences of the United States of America, 
104(44), 17406–17411. https://doi.org/10.1073/pnas.0703446104 
Streisinger, G., Walker, C., Dower, N., Knauber, D., & Singer, F. (1981). Production of clones 
of homozygous diploid zebra fish (Brachydanio rerio). Nature, 291(5813), 293–296. 
https://doi.org/10.1038/291293a0 
Tang, H., Xu, L., Liang, X., & Gao, G. (2018). Low dose dinaciclib enhances doxorubicin-
induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 
pathways. Oncology Letters, 16(5), 6608–6614. https://doi.org/10.3892/ol.2018.9474 
Tonder, M., Weller, M., Eisele, G., & Roth, P. (2014). Carboplatin and Etoposide in Heavily 





Traver, D., Herbomel, P., Patton, E. E., Murphey, R. D., Yoder, J. A., Litman, G. W., … 
Trede, N. S. (2003). The zebrafish as a model organism to study development of the 
immune system. Advances in Immunology, 81, 253–330. 
Tulotta, C., Stefanescu, C., Beletkaia, E., Bussmann, J., Tarbashevich, K., Schmidt, T., & 
Snaar-Jagalska, B. E. (2016). Inhibition of signaling between human CXCR4 and 
zebrafish ligands by the small molecule IT1t impairs the formation of triple-negative 
breast cancer early metastases in a zebrafish xenograft model. Disease Models & 
Mechanisms, 9(2), 141–153. https://doi.org/10.1242/dmm.023275 
Veinotte, C. J., Dellaire, G., & Berman, J. N. (2014). Hooking the big one: The potential of 
zebrafish xenotransplantation to reform cancer drug screening in the genomic era. 
Disease Models & Mechanisms, 7(7), 745–754. https://doi.org/10.1242/dmm.015784 
Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2003). The cell cycle: A review of 
regulation, deregulation and therapeutic targets in cancer. Cell Proliferation, 36(3), 131–
149. https://doi.org/10.1046/j.1365-2184.2003.00266.x 
Walker, D. H., & Maller, J. L. (1991). Role for cyclin A in the dependence of mitosis on 
completion of DNA replication. Nature, 354(6351), 314–317. 
https://doi.org/10.1038/354314a0 
Wang, F., Cao, Y., Ma, L., Pei, H., Rausch, W. D., & Li, H. (2018). Dysfunction of 
Cerebrovascular Endothelial Cells: Prelude to Vascular Dementia. Frontiers in Aging 
Neuroscience, 10, 376. https://doi.org/10.3389/fnagi.2018.00376 
Wang, S., Yao, F., Lu, X., Li, Q., Su, Z., Lee, J.-H., … Du, L. (2019). Temozolomide 
promotes immune escape of GBM cells via upregulating PD-L1. American Journal of 




Wang, Y. A., Elson, A., & Leder, P. (1997). Loss of p21 increases sensitivity to ionizing 
radiation and delays the onset of lymphoma in atm-deficient mice. Proceedings of the 
National Academy of Sciences of the United States of America, 94(26), 14590–14595. 
https://doi.org/10.1073/pnas.94.26.14590 
Weiss, R. B., & Issell, B. F. (1982). The nitrosoureas: Carmustine (BCNU) and lomustine 
(CCNU). Cancer Treatment Reviews, 9(4), 313–330. 
Wertman, J., Veinotte, C. J., Dellaire, G., & Berman, J. N. (2016). The Zebrafish Xenograft 
Platform: Evolution of a Novel Cancer Model and Preclinical Screening Tool. Advances 
in Experimental Medicine and Biology, 916, 289–314. https://doi.org/10.1007/978-3-319-
30654-4_13 
Westerfield, M. (2000). The zebrafish book. A guide for the laboratory use of zebrafish (Danio 
rerio). (4th edition). Eugene, Oregon: Univ. of Oregon Press. 
White, R. M., Sessa, A., Burke, C., Bowman, T., LeBlanc, J., Ceol, C., … Zon, L. I. (2008). 
Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell, 
2(2), 183–189. https://doi.org/10.1016/j.stem.2007.11.002 
Williams, G. H., & Stoeber, K. (2012). The cell cycle and cancer. The Journal of Pathology, 
226(2), 352–364. https://doi.org/10.1002/path.3022 
Wilstermann, A. M., Bender, R. P., Godfrey, M., Choi, S., Anklin, C., Berkowitz, D. B., … 
Graves, D. E. (2007). Topoisomerase II - drug interaction domains: Identification of 





Woolley, P. V., Dion, R. L., Kohn, K. W., & Bono, V. H. (1976). Binding of 1-(2-
chloroethyl)-3-cyclohexyl-1-nitrosourea to L1210 cell nuclear proteins. Cancer 
Research, 36(4), 1470–1474. 
Wu, C.-C., Li, T.-K., Farh, L., Lin, L.-Y., Lin, T.-S., Yu, Y.-J., … Chan, N.-L. (2011). 
Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. 
Science (New York, N.Y.), 333(6041), 459–462. https://doi.org/10.1126/science.1204117 
Xi, G., Hayes, E., Lewis, R., Ichi, S., Mania-Farnell, B., Shim, K., … Tomita, T. (2016). 
CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-kappaB pathway in 
multidrug-resistant glioblastoma cells in vitro. Oncogene, 35(42), 5576. 
https://doi.org/10.1038/onc.2016.64 
Xing, W., Shao, C., Qi, Z., Yang, C., & Wang, Z. (2015). The role of Gliadel wafers in the 
treatment of newly diagnosed GBM: a meta-analysis. Drug Design, Development and 
Therapy, 9, 3341–3348. https://doi.org/10.2147/DDDT.S85943 
Zhang, F., Qin, W., Zhang, J.-P., & Hu, C.-Q. (2015). Antibiotic toxicity and absorption in 
zebrafish using liquid chromatography-tandem mass spectrometry. PloS One, 10(5), 
e0124805. https://doi.org/10.1371/journal.pone.0124805 
Zhang, J., Stevens, M. F. G., & Bradshaw, T. D. (2012). Temozolomide: Mechanisms of 
action, repair and resistance. Current Molecular Pharmacology, 5(1), 102–114. 
Zhao, H., Tang, C., Cui, K., Ang, B.-T., & Wong, S. T. C. (2009). A screening platform for 
glioma growth and invasion using bioluminescence imaging. Laboratory investigation. 




Zhao, W., Sachsenmeier, K., Zhang, L., Sult, E., Hollingsworth, R. E., & Yang, H. (2014). A 
New Bliss Independence Model to Analyze Drug Combination Data. Journal of 
Biomolecular Screening, 19(5), 817–821. https://doi.org/10.1177/1087057114521867 
Zhou, Y., Wu, S., Liang, C., Lin, Y., Zou, Y., Li, K., … Yan, G. (2015). Transcriptional 
upregulation of microtubule-associated protein 2 is involved in the protein kinase A-
induced decrease in the invasiveness of glioma cells. Neuro-Oncology, 17(12), 1578–
1588. https://doi.org/10.1093/neuonc/nov060 
Zimmer, N., Kim, E., Sprang, B., Leukel, P., Khafaji, F., Ringel, F., … Tuettenberg, A. 
(2019). GARP as an Immune Regulatory Molecule in the Tumor Microenvironment of 




















NAME:  Mathew Stover 
PLACE OF BIRTH: 
 
Chatham, ON 







Tilbury District High School, Tilbury, ON, 2009 
 
The University of Western Ontario, B.M.Sc., 
London, ON, 2014 
 
